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Chapter 1 
1.1 INTRODUCTION TO HEPATITIS C TREATMENT 
1.1.1 Chronic hepatitis C infection 
Hepatitis A virus and hepatitis B virus were identified as the cause of infectious 
hepatitis and serum hepatitis respectively in the beginning of the seventies 1.3. After 
introduction of screening tests for hepatitis A and B 4 only 25% of the cases of post 
transfusion hepatitis were found to be caused by hepatitis B and none by hepatitis A. 
One or more viruses other than hepatitis A or B were suspected to be the cause of 
the remaining 75% of post-transfusion hepatitis. Initially, this hepatitis was named 
non-A, non-B hepatitis. After the discovery in 1989 of the hepatitis C virus (HCV), 
HCV was found to explain the large majority of post transfusion hepatitis 5,6. HCV is 
an enveloped, s'mgle-stranded RNA virus, approximately 50 nm in diameter, that has 
been classified as a separate genus in the Flaviviridae family J Occasionally acute 
viral hepatitis with jaundice occurs, but usually HCV presents as chronic hepatitis. In 
fact it appeared to be the most important causes of chronic viral hepatitis in Europe 
and the United States '. 
Chronic viral hepatitis is often asymptomatic or associated with non specific fatigue. 
The hepatitis (inflammation of the liver) is usually detected by an elevation of the 
enzyme alanine amino transferase which resides predominantly in hepatocytes. Over 
a period of 10 to 30 years chronic hepatitis C can induce fibrosis and cirrhosis 
followed by complications of cirrhosis or hepatocellular carcinoma 9. 
Even before the virus was discovered, interferon treatment for 6 months was shown 
to normalize Al T in about 50% of patients, with persistent normalization of Al T after 
discontinuation of therapy in about 20-25% of patients 10.11. With the availability of 
tests to detect the actual virus itself (polymerase chain reaction tests; PCR) , it 
became clear that the patients with a sustained biochemical response had cleared 
the virus, while in non responders the virus remained detectable. In a large 
multicenter Benelux study it was shown that early disappearance of HCV RNA from 
blood as well as earty normalisation of Al T were predictive of a sustained response. 
In fact the predictive value of a HCV test at 4 weeks had a very strong predictive 
value; detectable HCV RNA virtually eliminates the change of a sustained response 
12. Current studies use loss of HCV RNA as endpoint of treatment, since prolonged 
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disappearance of HCV RNA (>6 months) from the blood seems to indicate a genuine 
clearance of HCV infection (sustained response) 13. 
1.1.2 The problem in the treatment of chronic hepatitis C 
The first standard treatment for chronic hepatitis C were bases on randomised 
controlled trials reported in 1989 by Davis and 10.11. Since these reports, most 
treatment regimens in Western Europe and the United States uses a treatment 
schedule of 3 Mega Units (MU) IFN given subcutaneously thrice weekly (tiw). Initially 
the duration was 6 months, later 12 months became the standard therapy because of 
a lower relapse rate 14. The second standard was combination of interferon alpha 
with ribavirin after documentation in randomised controlled trials that the addition of 
ribavirin doubled the virological sustained response 15-18. Even with this improved 
treatment a sustained virological response only occurs in 40-45% of treated patients. 
The problem in the treatment of hepatitis C relates to the fact that more than 50% of 
patients are treatment failures. Certain baseline characteristics were found to be 
associated with nonresponse; sustained virological responses in patients with a 
genotype 1 infection were only about 20% 16·1'. 
1.1.3 The solution 
Assuming that HCV RNA negativity at 4 weeks is almost a prerequisite for a 
sustained response our interest focussed on following the decline in HCV RNA 
between start of treatment and 4 weeks. The development of a new diagnostic tool in 
the form of a PCR to quantitate HCV RNA in blood could make such type of 
monitoring possible 19. Furthermore, such an assay could allow us to assess within 4 
weeks the effect of changes in dose (10MU instead of 3MU Interferon) as well as 
changes in the frequency of administration (daily instead of three times a week) in 
those patients who did not respond to standard treatment. 
After having validated the assay on the Eurohep standard dilution panel 20 over a 
range of about 10E6 to 10E2 copies per ml, we could describe the actual decline in 
viral load between start of treatment and 4 weeks. The pattern of decline of HCV 
RNA during the first 4 weeks of treatment showed a 99% reduction in viral load in the 
first 2 days, followed by a steady, much slower decline over the following 26 days in 
most patients. The descriptive analysis of such a curve created the term viral kinetics 
15 
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which provided insight in the half-life of the virus as well as the numbers of particles 
produced each day. The mathematical modelling of virological and cell-biological 
processes induced by treatment created the concept of viral dynamics. So the 
studies assessing the role of quantitative HCV RNA rapidly became studies on viral 
kinetics and viral dynamics in chronic hepatitis C infected patients. 
1.2 AIM OF THE THESIS 
To explore the value of quantitative HCV RNA measurements in the management of 
patients with chronic hepatitis C undergoing anti-viral therapy: 
1) How does the hepatitis C virus decline after treatment initiation? 
2) What is the influence of dosage and frequency of Interferon on the viral 
decline? 
3) Can we mathematically model the decline in viral load? 
4) Can we use viral kinetics analyses for early dose reduction in the treatment of 
chronic hepatitis C? 
5) What are the possible biological mechanisms of interferon that explain the 
kinetics of the viral decline after treatment? 
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2.1 INTRODUCTION 
Therapy with alpha-interferon for chronic non-A, non-B hepatitis, developed in the mid-
eighties, was based on improvements in serum alanine aminotransferase (AL T) and 
liver histology. Since 1990 studies also aimed for clearance of hepatitis C virus (HCV) 
RNA from blood after the discovery of HCV and the development of a reverse 
transcriptase polymerase chain reaction (RT-PCR) in 1989 1.2. Since then, the 
endorsement of assessing HCV RNA by PCR before and during antiviral therapy has 
been clear and strong. However, the clinical advantages of testing HCV RNA by PCR 
compared to serum AL T are not entirely clear, but there are indications that RNA 
testing may be a more reliable parameter in determining the true response to interferon 
therapy. 
The clinical relevance of HCV RNA testing has been difficult to determine due to 
introduction of quantitative tests as well as the increasing sensitivity of HCV RNA-PCR 
tests. In 1998 the clinical significance of HCV RNA testing can be viewed from three 
angles: 
• generally accepted standard practice; 
• new developments 
• controversial issues. 
2.2 STANDARD PRACTICE FOR PATIENTS RECEIVING ANTIVIRAL THERAPY 
The two consensus reports published in 1997 3.4 recommend testing HCV RNA by 
PCR at 4 specific time points: 
a) before start of therapy 
b) after 12 weeks 
c) at the end of therapy 
d) 6-12 months after stopping therapy. 
In contrast, individual experts have concluded that the poorly standardized 
methodology and the high cost of testing HCV RNA restricted its clinical usefulness 5. 
Therefore, we discuss here the key data that - in all likelihood - were the basis for the 
recommendations of the consensus panels. 
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2.2.1 Hev RNA before start oftherapy 
Patients found to be anti HCV-positive with elevated serum AL T are considered 
patients with liver disease. and should undergo HCV RNA testing by PCR as part of 
the process of diagnosis. If the result is positive, the diagnosis of ongoing hepatitis C 
virus infection is confirmed. 
The need for antiviral therapy and the chances of sustained response should be 
established. In patients with active disease and signs of progressive fibrosis, chances 
of a sustained response to alpha-interferon are predominantly detenmined by three 
independent factors: 
• stage of the liver disease (cirrhosis), 
• virus genotype and 
• viral load 
In at least three studies &<l the level of viremia was on average predictive of the 
response to interferon. Non-responders had a threefold higher viral load than patients 
with a sustained response to interferon (Figure 1). Patients with high viremia had an 0-
7% chance of sustained response versus 15% for patients with low viremia 7. 
Figure 1 
8,-------------------------------------, 
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Nonresponse Response-Relapse Sustained AL T/RNA response 
AL T normal. HCV RNA negative 
Pretreatment HCV RNA levels measured by bDNA version I (corrected for genotype 2 and 3 sensitivity), 
and response to 6 months alpha-interferon (3 MU tiw). Results (expressed as mean (95% C.l.)) are from 
the Benelux study in 336 patients show a significant difference between sustained responders and other 
patients 8. 
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The strength of two predictors - stage of liver disease and genotype - is so pronounced 
., that we have not used quantitative HCV RNA for deciding whether to institute 
standard interferon therapy (3 MU thrice weekly). However, Reichard et al. 9 have 
recently demonstrated that the combination of interferon and ribavirin is superior to 
interferon monotherapy in patients with viral load above 3 million genome-
equivalents/ml. We therefore predict that a quantitative assessment of HCV RNA will 
become considered clinically useful for deciding the type and possibly duration of 
therapy, as reliable quantitative tests for HCV RNA become increasingly more 
available. 
2.2.2 HCV RNA after 12 weeks 
Patients on antiviral therapy for chronic hepatitis C have a 5-50% chance of obtaining a 
sustained response. In view of the cost and side-effects of antiviral therapy, non-
responders should be identified early in the course of therapy. 
Patients who do not have normal serum AL T after 12 weeks of standard treatment are 
very unlikely to respond to further treatment, according to expert opinion 5.10. However, 
this criterion is not generally confirmed. Experience from a Califomian group, that used 
a PCR with a high sensitivity level of (100 copies/ml), indicates that HCV RNA testing 
at 12 weeks actually provides more accurate information than AL T ". At week 12 of 
treatment of the sustained responders 7% (1 out of 15) were still HCV RNA positive 
whereas 33% (5 out of 15) had abnormal ALT. It is unclear whether this latter figure 
reflects a patient population with a high degree of steatosis or a different method for 
setting the upper limit of the normal value. However, the AL T level is quite sensitive to 
other factors including the toxicity of interferon if used in higher doses. 
Therefore, to avoid making an important clinical decision solely on one AL T value, it is 
recommended that both AL T and HCV RNA by PCR be measured at week 12; those 
with an abnormal AL T and a positive HCV RNA test should stop therapy. 
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2.2.3 HCV RNA at the end of therapy 
Patients at the end of therapy who have a normal AL T are considered biochemical 
responders, but many will relapse in the 6-12 months period after stopping therapy. 
Biochemical relapse is significantly more frequent in patients with a positive HeV RNA 
test by peR at the end of treatment (95%) than in those with a negative HeV RNA test 
(57%) '. Another important justification for testing HeV RNA by peR at the end of 
therapy in individual patients is that it provides an important guide for further therapy in 
case of relapse. If HeV RNA is negative, the original therapy might be reinstituted with 
appreciable chance of sustained response with longer therapy; if HeV RNA is positive 
at the end of therapy, retreatment with the same schedule is universally unsuccessful 
12 
2.2.4 HCV RNA 6-12 months after stopping therapy 
Patients who are followed 6-12 months after discontinuation of therapy and then have 
normal serum AL Ts are temned sustained (biochemical) responders. Assessment of 
HeV RNA by peR is then useful: absence of HeV RNA documents "cure" 10 but the 
presence of HeV RNA reflects a more than 50% chance of relapse in the following 5 
years 11,13 (Figure 2). It is therefore recommended to measure both ALT and HeV RNA 
by peR 6-12 months after stopping therapy to reliably predict the long-term outcome. 
In trials, the time of this assessment is usually 6 months after stopping therapy; in 
clinical practice there is a slight improvement in the predictive value of the test if the 
assessment is done 12 months after stopping 10. 
Thus, the standard 1997 practice for assessing HeV RNA by peR in patients 
undergoing antiviral therapy has clinical significance for each time point. These 
assessments are now considered essential for clinical trials; and - if reliable testing is 
available - should be introduced in clinical practice. 
23 
Chapter 2 
Figure 2 
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Probability of maintaining normal serum alanine amino-transferase levels at long-term follow-up (Kaplan-
Meier curves) in patients groups with a sustained biochemical response, 12 months after discontinuation 
of a treatment with alpha-interferon. In HCV RNA positive patients ( -- ), the probability of hepatitis 
relapse is 53%, 4 years after therapy; in HCV RNA negative patients (-.- ), the probability is 0% (Iog-
rank test; P < 0.001) 
(adapted with permission of Chemelfo et al. 10) 
2.3 NEW DEVELOPMENTS 
The consensus reports recommended a decision to stop or continue treatment on the 
basis of the AL T and HCV RNA determination at week 12. This recommendation was 
based on the observation that nearly all patients who achieved a biochemical end-of-
treatment response had normal ALT levels by treatment week 12 14.15; in addition 
testing HCV RNA by PCR at week 12 was said to be sensitive and specific for the 
outcome of treatment 16. 
New insights in viral kinetics 17,18 have focussed attention on several reports 
mentioning week 4 after start of therapy as a clinically useful time point for predicting 
outcome of therapy. In addition, the changing sensitivity of HCV RNA-PCR makes it 
imperative to include quantitative measurement of HCV RNA into the discussion. 
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Therefore, the following sections will discuss new developments with regard to the 
questions: 
a) Is a qualitative HeV RNA test earlier than week 12 advantageous for clinical 
decision-making about continuing or stopping interferon treatment? 
b) Is quantitative HeV RNA testing advantageous? 
2.3.1 Early HeV RNA testing 
In the early phase of the Benelux study 2, it was observed that HeV RNA had 
disappeared from plasma by week 4 in some patients, and that HeV RNA 
measurement at that time might have a high predictive value. In the final study results 
" the predictive value of a positive test for non-response was 98% and the predictive 
value of a negative test for sustained response was 34%. Along the same line, Karino 
et al. 19 reported that in 114 patients that had received alpha-interferon therapy for six 
months, no sustained responders were found in more than 50 patients with HeV RNA 
positivity at week 4. The percentage of sustained responders was highest (76%) in 
those with undetectable serum HeV RNA at week 1, and decreased weekly till week 4 
(Figure 3). 
A Spanish study comparing the predictive value of HeV RNA at week 4 that of serum 
ALT confirmed the high clinical relevance of testing HeV RNA by peR at week 4 20. 
The predictive value of a negative HeV RNA test or normal AL T for a sustained 
response and that of a positive HeV RNA test or raised AL T for patients without a 
sustained response is given in Table I. These findings have been confirmed in smaller 
studies 21,22, 
Testing HeV RNA at week 4 therefore seems the best way to identify sustained 
responders and exclude almost all those patients that will not show a sustained 
response. By testing Hev RNA at week 4 of the treatment one could predict response 
or non-response early and avoid unnecessary treatment and cost 11 in many patients, 
that will become non-responders. Several studies '.19 show that week 4 analYSis of 
HeV RNA does not exclude a large percentage of potential sustained responders. 
While these studies suggest week 4 rather than week 12 should be the time point of 
measurement, there are arguments which would advise against this at the present 
time. The Hev RNA-peR tests that were basic to the evidence had a detection limit of 
1000-2000 copies per ml. With enhanced sensitivity of Hev RNA-peR to 100 copies 
per ml 11 it is readily understandable that HeV RNA negativity will occur later in many 
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patients. Therefore the time to propose amendments to the consensus reports will be 
related to the general availability of quantitative HCV RNA. 
Figure 3 
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Sustained response rate by time point of negativity of serum HCV RNA to IFN therapy in 114 patients 
with chronic hepatitis C receiving interferon therapy for 6 months. 1WH, 2W(-) and 4W(-) indicate 
HCV RNA negative patients at the first, second and fourth week of therapy, respectively, 4W(+} 
indicates patients who showed serum HCV RNA positivity throughout the first four weeks of therapy. 
SR indicates sustained responders; non-SR other type of response (non-response or relapse). 
(adapted wfth permission of Karina et a/. 19) 
Table 1: Predictive values of HCV RNA and AL T at 4 and 12 weeks of treatment 
HCV RNA week 4 
HCV RNA week 12 
ALT week 4 
ALT week 12 
From: Gavier B et a!. 20 with permission. 
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Predictive value (%) 
negative test for 
sustained remission 
50 
44 
41 
34 
positive test for no 
sustained remission 
95 
93 
78 
78 
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2.3.2 Quantitative RNA testing 
The predictive value of a HCV RNA-PCR test at a certain moment is dependent on 
both the velocity in the decrease of viral load during therapy and the sensitivity of the 
test used. When there is a gradual decrease in plasma HCV RNA concentration, a test 
with a higher sensitivity will remain positive for a longer period of time than a less 
sensitive test (Figure 4). Therefore, a better prediction of response or non-response 
might be achieved by determining the early kinetics of the hepatitis C virus after start of 
interferon therapy, with a highly sensitive test. 
Figure 4 
v .i~ra~I~lo~a~d~,~c~o~p~ie~s~/m~I~ ____ , r---------------------, 107r [;IDR -RR 
-SR 
below detection by superquant 
1010L----------.J 
1 2 3 14 28 
days after start high dose IFN 
The effeet ofinereased sensitivity ofHCV RNA tests on the time~point ofHCV RNA negativity. In a 
hypothetical patient the decline in vrralload is depicted over time of interferon therapy. HeV RNA becomes 
negative at week 2 when using an insensitive bDKA test; increase in assay sensitivity will cause HeV R.~A 
result to remain positive for a longer period of treatment. 
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Close examination of the kinetics of the hepatitis C virus reveals the crucial importance 
of an early response of the virus to interferon. Measurements from studies of viral 
kinetics reveal a very short viral half life of approximately 2-8 hours and a very high 
production rate of about 10E11 viral copies per day 17.18 Moreover, even after a few 
days there are significant differences in the drop in viral load between patients that will 
become responders and those that will remain HCV RNA positive after treatment 18 
(Figure 5). These observations suggest that a reaction to medication can be expected 
early after the start of treatment and - vice versa - that non-response also can be 
determined early. Thus, quantitative HCV RNA measurement could prove a very 
welcome tool for decision making. 
This discussion is becoming more clinically relevant through the emergence of a HCV 
RNA test, that is quantitative, has equal senSitivity for known genotypes, a detection 
limit of 100 copies/ml, and a cost comparable to that of a liver biopsy (Superquant™, 
National Genetics Institute, Los Angeles, USA). Other manufacturers of HCV RNA-
PCR tests should follow rapidly with similarly qualified assays. 
Figure 5 
viral load (copies/ml) 
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Results of viral kinetics study in 11 patients treated with an 'Initial high da'lly dose of alpha-interferon. 
Differences in the drop in viral load between non-responders and responders become clear after day 2, 
No easy discrimination can be made between sustained responders and response relapsers in this study 
with early viral load measurement. 
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Patients who have insufficient suppression of HCV RNA (for instance, levels above 
2000 copies/ml after 4 weeks of interferon monotherapy) should stop that regimen. 
This is particularly important because it has been confinmed that patients without 
clearance of HCV RNA from blood at 4 weeks of therapy frequently relapse after 12 
months of interferon therapy. 
Another way of assessing response to therapy is to calculate the drop in viral load at 
the end of 4 weeks of therapy. Several studies in a limited number of patients suggest 
that responders can be separated from non-responders by the percentage reduction of 
viral load from baseline 23 or by the reduction in viral load expressed in log units 24 
The development of early quantitative HCV RNA testing therefore has clinical 
relevance, since it may allow a decision on response or non-response about 8 weeks 
earlier in most patients; this is beneficial for the patient and reduces cost in case of 
non-response. It is clear that implementation of early quantitative HCV RNA testing 
should only be done when a validated HCV RNA test is available for the physician in 
care of the patient. 
2.4 CONTROVERSIAL ISSUES 
Identification of non-responders during therapy is quite reliable with current tests and 
therapies. However, identification of sustained responders - vs. potential relapsers -
among patients without detectable serum HCV RNA after 6-12 months of therapy is 
unreliable. 
The clinical significance of this test in relation to complexicity and costs is under 
debate. We will therefore discuss the following two topics: 
a) can testing of HCV RNA in the liver or peripheral blood mononuclear cells 
(PBMC) be useful for clinical deCision-making? 
b) the complexicity and costs of HCV RNA testing. 
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2.4.1 Can testing of HCV RNA in the liver or PBMC be useful for clinical decision 
making? 
Since hepatitis C is a viral infection affecting the liver, it is logical to be interested in the 
viral load in the liver. Again, the availability of an accurate quantitative test with high 
sensitivity makes the study of this question possible. Schlaak et al. 25 have described 
how the viral load per liver cell is significantly lower in those patients that will become 
sustained responders compared to non-responders. 
However, the clinical relevance of testing the liver might be greater after treatment than 
before therapy. Conceivably, patients with undetectable serum HCV RNA by PCR at 
the end of therapy but still with HCV RNA positivity in the liver, will become relapsers -
whereas those that have cleared HCV from the liver will be the sustained responders 
26-28 
Partly because of easy accessibility, investigators have examined HCV RNA in PBMC 
in order to answer the same question of cellular viral persistence and correlation with 
relapse. Current data are inconclusive, in view of the low number of patients tested 
28.2", Further data should be accumulated with the use of validated methodology. 
2.4.2 Complexicity & costs 
Until recently, HCV RNA-PCR testing was complex and costly. Preparation of serum or 
plasma had to be undertaken within 2 hours of drawing blood, with subsequent storage 
at -20°C or below. Since both in-house PCR and commercial assays often had 
methodological problems 30.31 the clinician had to ask about negative controls 
(specificity), low positive controls (sensitivity) and - in case of quantitative assays - for 
results of dilution series and which standard was used. However, with the advent of 
plasma preparation tubes (Becton Dickinson MEYLAN Cedex-France), and validated 
assays 18 the complexicity of HCV RNA-PCR testing will disappear rapidly. 
In relation to costs, our approach follows that of Tong et al. 11 When a treatment 
costing several thousand dollars is contemplated, it seems prudent to establish the 
need for therapy. Therefore the initial work-up should include a liver biopsy and an 
HCV RNA-PCR test, both costing $ 150 - $ 250.-
The use of HCV RNA-PCR testing early in treatment is extremely cost effective, 
leading to overall savings of 30% or more ". 
The cost-effectiveness of HCV RNA-PCR testing at the end-of therapy and during 
follow-up are debatable. However, at present they provide more prognostic information 
30 
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than a liver biopsy, which is often included in evaluation of therapy and has similar 
cost. Furthenmore, the information, provided by an Hev RNA-peR test at the end of 
therapy may be of value for choosing a treatment schedule in case of relapse. 
In conclusion, the evidence presented here suggests that Hev RNA-peR testing 
before therapy and three times thereafter is good clinical practice and can save overall 
costs. 
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3.1 ABSTRACT 
Background. The quantitative measurement of HCV has become an important 
diagnostic and prognostic tool for the initiation and follow-up of treatment of patients 
chronically infected with hepatitis C virus (HCV). These techniques are changing 
constantly, and continuous adaptations have to be made. 
Objectives and study design. The aim of this study was to validate the currently 
used PCR amplification techniques (COBAS Amplicor v2.0 and SuperQuant), and 
position them in relation to the Quantiplex bDNA 2.0 signal amplification assay. 
Results. Regression analysis of the two PCR based amplification assays indicated a 
high correlation (P<0.0001) for both HCV genotype 1 as well as for HCV genotype 
non-1 specimens. Furthermore, Bland-and-Altman analysis clearly indicated that the 
differences between these two assays were independent of the viral load measured. 
We observed that validation of these assays using the Pel'lcheck HCV-RNA panel 
indicated that although both assays gave similar results, the SuperQuant assay, 
which is performed in an external reference laboratory, was more genotype 
dependent. Furthermore, the claimed detection level of this assay could not be 
confirmed using this reference panel, and the detection level of both PCR based 
assays were more identical than suggested previously. 
Comparison of these two PCR based assay with the Quantiplex bDNA 2.0 assay 
showed a more clear correlation with the HCV non-1 genotype samples (r=0.893 for 
SuperQuant, and r=0.932 for Cobas Amplicor) than with the HCV genotype 1 
samples (r=0.734 for SuperQuant, and r=0.898 for Cobas Amplicor). However, 
regression analysis identified in all cases a slope significantly different from 1. 
Conclusion. Both PCR based assays can be used for the quantification of HCV. 
Improvements of commercially available PCR based assays warrant their use in a 
diagnostic setting. The use of the currently available Quantiplex v2.0 assay is limited 
due to its detection limit. Further effort and implementation of standardization is 
needed. 
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3.2 INTRODUCTION 
It has been estimated that world-wide over 170 million individuals are chronically 
infected with the hepatitis C virus (HCV) 1,2. Measurement of HCV RNA in serum or 
plasma has been used extensively as a prognostic marker for individuals undergoing 
treatment with interferon alone or in combination with ribavirin 3-'. The ability to 
quantify HCV RNA accurately is important in chronic hepatitis C infections as the 
pretreatment level may predict the response to therapy, Furthermore, viral kinetics 
can predict an early response to therapy in chronic hepatitis C infections, identifying 
patients who will or will not benefit from therapy 4,9,10. The quantitative measurement 
of HCV RNA can also be useful to identify and monitor patients with an incomplete 
response or relapse, The optimal time to measure HCV RNA to predict response in 
an individual patient undergoing therapy is not exactly known, but available data 
indicate that early measurement may be important 3,S 
Techniques to measure HCV RNA both qualitatively and quantitatively are changing 
constantly, but results from different studies cannot be compared easily due to lack of 
standardization ", Furthermore, commercial assays are subject to continuous 
adaptations to detect different genotypes equally. with increasing sensitivity 12-16, 
In this study, we evaluated three available commercial assays for the quantitative 
detection of HCV RNA. Two of these assays are PCR based, the COSAS Amplicor 
2,0 (Roche Diagnostics), and the SuperQuant assay (National Genetics Institute), 
The latter is performed in an external central laboratory, One signal amplification 
assay, the Quantiplex bDNA 2.0 (Sayer Diagnostics) is included. Their use in a 
routine diagnostic laboratory is discussed, 
3.3 PATIENTS AND METHODS 
3.3.1 Patients and samples 
Plasma and serum samples from thirteen patients with a laboratory confirmed 
chronic hepatitis C infection undergoing alpha interferon therapy were used in this 
evaluation_ Samples were drawn for the quantitative analysis of HCV RNA, and an 
average of 14 samples was analyzed from each patient Samples were aliquoted and 
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frozen at -80°C within 2 hours after collection. This sample management provides the 
optimal condition for reliable results U 
3.3.2 Genotyping of hepatitis C virus 
EDT A plasma samples were selected for sequence analysis. The genotype of the 
hepatitis C virus was determined with primers directed against the conserved 
sequences of the 5' non-coding region [cDNA primer 5'-GTG. CAC. GGT. CTA. CGA. 
GAC. CT, primer HCV2 5'-nG. GCG. GCC. GCA. CTC. CAC. CAT. GAA.]. 
Sequences reactions were performed on a Vistra Labstation (Amersham Pharmacia 
Biotech, Buckinghamshire, United Kingdom) using dye terminator chemistry and 
analysed on an Applied 373 automated sequencer (Applied Biosystems, 
Nieuwerkerk, The Netherlands). Both strands were sequenced and analysed using 
Geneworks software (Oxford Molecular, Oxford, United Kingdom). The genotype was 
determined according recommendations of the International HCV Collaborative Study 
Group 18 The thirteen patients were included proved to be infected with the HCV 
genotypes 1a (n=2), 1b (n=5), 2a (n=3), 3a (n=1), 3b (n=1), and 4a (n=1). 
3.3.3 Quantiplex HCV RNA 2.0 Assay (bONA) 
The Quantiplex HCV RNA 2.0 assay (frorn Bayer Diagnostics, formerly Chiron 
Diagnostics) is a signal amplification nucleic acid probe assay for the quantification of 
HCV RNA in serum or plasma. The conserved 5'-noncoding region and part of the 
core region are used as targets for detection. HCV RNA is captured into wells coated 
with specific synthetic oligonucleotide target probes. A second set of target probes 
hybridises to the viral RNA. Branched DNA amplifiers and alkaline-phosphatase 
conjugated probes subsequently amplify the signal. The whole process is performed 
in a semi-automated Quantiplex bONA System 340, which automatically performance 
the incubation, plate sealing, washing, reading, data processing, and reduces the 
hands-on labour requirements. Each plasma samples is tested in duplicate (50 ~I per 
assay) and the concentration of HCV RNA is calculated as the mean of the two test 
results. The sensitivity of the bONA version 2.0 assay is claimed to be 200,000 RNA 
copies per ml, with an upper limit of detection of 120 million RNA copies per ml. 
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3.3.4 COSAS Amplicor Monitor v2.0 Assay 
The Cobas Amplicor Monitor v2.0 assay (called COSAS Monitor, Roche Molecular 
Systems) is a semi-automated target amplification assay for the quantification of 
HCV RNA in plasma or serum. The measurement of HCV RNA is carried out using 
an internal quantification standard (OS), which is a non-infectious RNA transcript 
that contains the identical binding sites as the HCV target and a unique primer 
binding site that distinguishes the OS RNA from the HCV amplicon. The OS is added 
during the sample preparation step, therefore enabling to correct for loss of HCV 
RNA during the whole procedure, and opens the possibility to monitor inhibition of the 
sample during the amplification step. The amplification and detection is performed 
automatically on the Cobas Amplicor. Samples with an optical density above 3.0 are 
recommended to be adequately diluted to ensure proper quantification. The detection 
range of this assay is according the manufacturer, between 1000 and 1 million HCV 
RNA copies per ml. 
3.3.5 SuperQuant HeV quantification 
A protocol for this assay (SuperOuant HCV) is performed and developed at the 
National Genetics Institute, Los Angeles, U.S.A. 19. RNA is extracted from serum 
using a guanidinium thiocyanate phenol chloroform mixture followed by an ethanol 
ammonium acetate precipitation 20 Extracted RNA for each sample is converted to 
cDNA in two separate reverse transcription reactions using random 
hexadeoxyribonucleotide primers and this cDNA is immediately used as a template 
for the PCR amplification using two different primer sets both from the 
5'nontranslated region of HCV. The cDNA is split evenly and amplified in four 
separate PCR reactions terminated each at different cycle numbers. This enables 
both accurate quantification and sensitivity for each sample. Known numbers of 
diluted standards are included in the process to construct standard curves for 
quantitative measurement. The lower detection level is claimed to be less than 100 
HCV RNA copies per ml 21. An internal standard is used to monitor sample inhibition. 
The whole process of agarose gel electrophoresis of the PCR product, followed by 
Southern blotting, hybridisation and detection using a digoxigenin labelled DNA 
probe is performed automatically. The range of the SuperQuant assay is claimed to 
be between 100 and 5,000,000 HCV RNA copies per ml. 
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3.3.6 Pelicheck HCV·RNA panel 
The Pelicheck HCV reference panel (Viral Quality Check -VQC· CLB, Amsterdam, 
The Netherlands) contains dilutions of the EUROHEP genotype 1 and 3 plasma 
standards. These standards have been extensively characterised in the collaborative 
EUROHEP study, and have been prepared from a plasma pool negative for HBsAg, 
anti·HBc, anti·HCV, anti·HIV·1/s, anti·HTLV·1, syphilis, HCV RNA, HBV DNA and 
HIV·1 RNA. The HCV RNA type 1 contains 36,000 genome equivalents per ml, while 
the HCV RNA type 3 contains 120,000 genome equivalents per ml ". The same lot 
of Pelicheck HCV RNA panel was used in our analysis of both the SuperQuant and 
the COBAS Amplicor assay. 
3.3.7 Statistics 
Logarithmic transformation of the readings of the different assays was carried out. XY 
scatter diagrams were drawn and the correlation coefficients (r") or Spearman 
correlation r as well as the linear regression analysis was done using the statistical 
functions of SPSS 9.0 software. Ninety·five percent confidence interval were 
calculated using the Fisher's Z transformation method. 
In order to compare to what extent the data obtained with the COBAS Amplicor 
assay agree with the data obtained with the NGI assay, the data were furthermore 
analysed as described by Bland and Altman 22. This analysis is based on comparing 
the differences between measurements for the same sample by plotting the 
differences against the average. 
3.4 RESULTS 
3.4.1 Pelicheck HCV·RNA panel 
The HCV reference panel was used to evaluate the sensitivity and the linearity of 
both the NGI SuperQuant and the Roche COBAS Monitor assay. Furthermore, 
because two genotypes of HCV (genotype 1 and 3) are included in this panel, 
information on genotype dependency of the assays becomes available (Figure 1). 
The viral load of this reference panel is below the detection level of the bONA assay, 
therefore no data for this assay are available. 
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Both assays were able to detect and quantify HCV genotype 1 equally well within 
two-fold of the assigned value. The COBAS Monitor assay proved to slightly 
overestimate the number of HCV RNA copies per ml (1.5 fold), in contrast to the 
SuperQuant assay for which values were around the actual assigned HCV RNA copy 
number. However, both assays were unable to detect the dilutions calculated 225 or 
less HCV RNA copies per ml. 
For the HCV genotype 3, the COBAS Amplicor assay slightly underestimated the 
values assigned to the panel by not more than two-fold. The SuperQuant assay, 
however, had difficulties to detect the high HCV RNA copy number of this genotype 
(120,000 HCV RNA copies per ml) with a 10-fold differences. Both assays detected 
the lowest assigned value of 1200 HCV RNA copies per ml in this panel, but not the 
300 HCV RNA copy number. 
Figure 1 
PeliCheck HCV RNA panel genotype 1 and 3 
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COBAS Amplicor PCR __ 
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100 1000 10000 100000 1000000 
copies HCV RNA per ml calculated 
The Iinear'lty of the Roche COBAS Amplicor v2.0 assay HCV RNA assay (marked with black lines) and 
the NGI SuperQuant assay (marked with gray lines) was determined using the Pelicheck HCV RNA 
panel. This panel contains assigned HCV RNA dilutions of genotype 1 and 3. These assigned values 
were compared to the calculated line and expressed as HCV RNA copies per ml (calculated line). 
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3.4.2 Quantification of HCV RNA by PCR based assays 
The COSAS Amplicor and the SuperQuant assay were compared to determine their 
usefulness for a clinica[ laboratory. by comparing the HCV RNA values in patient 
samples during treatment for each type of assay. Furthermore, to establish to what 
extent these assays quantified HCV RNA of different genotypes, we divided the 
obtained HCV RNA values between patients infected with HCV genotype 1 (n=7), 
and patients infected with HCV genotype non-1 (n=6). 
One-hundred-sixty-one samples were analysed in both the SuperQuant and COSAS 
Amplicor assays. The samples analysed with the COSAS Amplicor assay were 
diluted in negative plasma if the optical density was above 3.0. Furthermore, the 
samples were divided into HCV genotype 1 (n=77) and HCV genotype non-1 (n=84) 
samples. The log values were plotted (see Figure 2A) and regression analysis 
showed that both datasets were highly correlated for HCV genotype 1 (r =0.922, 
p<0.0001) and HCV genotype non-1 (r =0.933, p<0.0001). Furthermore, regression 
analysis showed that the slope for both HCV genotype 1 as well as HCV genotype 
non-1 approached 1 (HCV genotype 1: slope 0.965,95% confidence interval 0.872 to 
1.058; HCV genotype non-1: slope 0.937; 95% confidence interval 0.858 to 1.016), 
while the y intercept approached 0 (HCV genotype 1: y intercept -0.111, 95% 
confidence interval -0.591 to 0.369; HCV genotype non-1: y intercept -0.062; 95% 
confidence interval -0.472 to 0.348). 
Siand-and-A[tman analysis furthermore indicated that the difference between both 
assays were independent from the average values measured, since both for HCV 
genotype 1 and HCV genotype non-1, the slope did not significant differ from 0 (HCV 
genotype 1: slope -0.049,95% confidence interval -0.140 to 0.045; HCV genotype 
non-1: slope -0.004, 95% confidence interval -0.086 to 0.077). From these data it 
could furthermore be concluded that both for HCV genotype 1 and non-1, the 
assigned values by the COSAS Amplicor assay were higher than the assigned 
values by the SuperQuant assay. However, regression analysis showed that these 
differences indicated by y intercept of the Siand-and-A[tman analysis were not 
significantly different from 0 (HCV genotype 1: y intercept 0.518, 95% confidence 
interval -0.054 to 0.982; HCV genotype non-1: y intercept 00400, 95% confidence 
interval -0.007 to 0.806). 
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performed for both groups of HCV genotypes. Values are given in copies HCV RNA per ml plasma. 
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3.4.3 Correlation of PCR based assays with the Quantiplex HCV RNA 2.0 assay 
To demonstrate whether the two currently used PCR based assays can be used 
aside the Quantiplex bONA 2.0 assay, samples were analysed by the three 
respective assays. Currently only samples above the detection limit of the Quantiplex 
bONA 2.0 assay can be included (200.000 HCV RNA copies per ml). Samples were 
divided in HCV RNA genotype 1 (Figure 3a) and HCV RNA genotype non-1 (Figure 
3b). The Quantiplex bONA assay gave consistently higher values than both the 
COSAS Amplicor and the SuperQuant assay. For the HCV genotype 1 samples, the 
bONA assay gave 0.197Log higher results than the COSAS Amplicor assay, and 
0.539Log higher results than the SuperQuant assay. For the HCV non-1 genotypes, 
this was respectively 0.292Log and 0.626Log values. 
Soth the PCR based assays do highly correlate with the Quantiplex bONA assay for 
HCV non-1 genotypes (r =0.893 for SuperQuant, and r =0.932 for the COBAS 
Amplicor assay). Regression analysis showed however that the slope of the curves 
did significantly differ from 1 (Quantiplex slope = 0.846, 95% confidence interval 
0.699 to 0.992; COSAS Amplicor assay slope = 0.854, 95% confidence interval 0.747 
to 0.960). Analysis of the HCV genotype 1 samples showed the best correlation 
between the COSAS Amplicor assay and the Quantiplex bONA assay (r = 0.898, 
slope 0.888, 95% confidence interval 0.782 to 0.993). The correlation with the 
SuperQuant assay for HCV genotype 1 was less (r =0.734), with a slope of 0.505 
(95% confidence interval 0.342 to 0.668). 
46 
Figure 3 
8,0 
7. 
7,0 
6,5 
< 0 z 6,0 ~ 
! 
" • 
5,0 
4,5 
4,0 
4,0 4,5 5,0 
8,0 
7,5 
7,0 
6,5 
~ 6,0 ~ 
! 5,5 
5,0 
4,5 
4,0 
4,0 4,5 5,0 
can we routinely quantify HCV RNA 
Comparison HCV Genotype 1 
5,5 6,0 6,5 
• 
Y" 0.888x + 1.063 
R" 0.898 
CaSAS Ampllcor· bDNA 
7,0 7,5 
Log COSASAmpJlcororSuporQu:mtHCV RNA 
Comparison HCV Genotype non-1 
• 
5,5 6,0 6,5 
o 
• 
y"O.854x+1.165 
R" 0.932 
COSAS Ampllcor· bDNA 
7,0 7,5 
Log COSAS Ampllcoror SuporQuont HCV RNA 
A 
8,0 
B 
8,0 
HCV viral loads in clinical samples determined with the Quantiplex bONA 2.0 signal amplification 
assay and the relation with the COSAS Amplicor 2.0 (represented with closed diamonds) and the 
SuperQuant assay (represented with open squares). The correlation between both these assays are 
divided into samples with HCV genotype 1 (Panel A) and samples with HCV genotype non-1 (Panel 
B). The equation of the regression curve and the Spearman correlation coefficient R is given for each 
group of samples. Values are given in copies HCV RNA per ml plasma. 
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3.4.4 Clinical monitoring 
To further demonstrate the clinical utility of the respective HCV RNA detection 
assays, chronically infected HCV patients treated with interferon were monitored with 
all three assays during the first period of this treatment. The appropriate dilutions 
were made in order to enable accurate determinations. The detection limit of the 
respective assays were used according the manufacturers information. In Figure 4, 
the calculated Log HCV RNA levels in copies per ml, measured with the respective 
assays were plotted for the three different assays. The data from three patients 
shown were infected with HCV genotypes 1 b, 2a and 3b, respectively. Although all 
patients showed a similar rapid decline in HCV RNA levels, differences were 
observed due to differences in standardization and detection limits. Furthermore, in 
Figure 4A is can be clearly observed that the SuperQuant assay underestimates 
some individual samples from this patients, compared to the other two used assays. 
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3.5 DISCUSSION 
The accurate measurement of HCV RNA is serum or plasma is becoming more and 
more important for individual patient management in a routine diagnostic setting. 
Data from large clinical trials have given convincing (clinical) evidence that the 
measurement of HCV RNA is an important factor in predicting the therapeutic 
response to interferon or combination therapy of interferon and ribavirin in patients 
chronically infected with HCV 7.23-20. Furthermore, the HCV genotype has been 
implicated as a predictive factor, although the quantification of different genotypes 
has been a problem for several of the first generation of assays 6. It should be clearly 
stated, however, that a large amount of these data in clinical trials have been 
generated using the PCR based, only externally available SuperQuant assay. No 
validation of this assay has been performed with the currently in use COSAS 
Amplicor assay, and no infomration is available whether this SuperQuant assay has 
been improved (or not) during the last years. Commercially available assays, which 
are currently available for routine in-house testing, have been changing constantly, 
and further improvements both in sensitivity and automation are to be expected in the 
next years 26-28, 
In this study, we have evaluated the currently available assays for their use in a 
diagnostic setting, of which an essential part was the positioning of the SuperQuant 
PCR assay in relation towards the semi-automated COSAS Amplicor 2.0 assay and 
the Quantiplex bDNA 2.0 assay. This comparison is necessary because diagnostic 
laboratories have to assist in the implementation of the recommendations on the 
treatment of chronic HCV infections, like established at the International Consensus 
Conference on Hepatitis C 29. 
From our data we could clearly conclude that there was a good correlation between 
the SuperQuant and the COSAS Amplicor 2.0 assay, both for HCV genotype 1 and 
HCV genotype non-1 samples. From regression analysis it could furthermore be 
concluded that both assays generated statistically significant related results, and that 
differences between these assays were independent from the average result. 
Although the COSAS Amplicor assay assigned higher values than the SuperQuant 
assay to the samples, these differences were not statistically different for the total set 
of data. Generally, data are generated for large studies, in which datasets from 
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individual patients will not influence the total outcome of the study. Looking at data 
from individual patients under treatment, like represented in Panel 4A, one could 
conclude however, that the SuperQuant assay underestimated HCV RNA values 
compared to both the Quantiplex or COBAS Amplicor assay. The large differences 
could most likely not been discovered due to the manner the assay is set up. In the 
COBAS Amplicor assay, an internal standard is used during the whole procedure and 
corrects for both loss of samples as well as inhibition of the amplification reaction. 
From the analysis of the data from the Pelicheck HCV RNA panel, we could also 
conclude that the detection level for both PCR based assays were similar. Both 
assays could not detect less than 900 HCV RNA copies per ml. This indicates that 
the claimed detection level of 100 copies per ml for the SuperQuant assay is based 
on a different standard. Furthermore, the assay seems to be more genotype 
dependent than the COBAS Amplicor assay, definitely for the HCV genotype 3. No 
data are available for the other genotypes. 
Comparing both PCR based assays with the Quantiplex bONA 2.0 assay, indicated 
that although both correlate with this signal amplification assay, the slope of the 
curve did not reach 1. For the SuperQuant HCV genotype 1 comparison, the slope 
was even far from 1. These differences could be due to the intrinsic differences 
between signal and target amplification assays. The lack of sensitivity of this assay 
however, makes routine implementation not feasible. 
Since the introduction of quantitative assays the detection of HCV RNA, many 
improvements have been made, both in detecting different genotypes of HCV and 
improvement of the detection level 27.30.31. New generation of assays, similar to the 
new generation of Quantiplex bONA assay for HIV-1, as well as developments in 
real-time amplification technology will be introduced in the near future. The final steps 
towards full proof introduction of quantitative detection techniques are automation 
and standardization. The introduction of an international standard for HCV has been 
initiated, although limited information is available on conversion towards currently 
used assay systems, stability in time. Furthermore, only HCV genotype 1 is included 
in this international standard. 
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In conclusion, our results indicate that there are no differences in the available peR 
amplification assays. This enables the introduction of these assays in a routine 
diagnostic setting, enabling to support individual patient management. 
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4.1 ABSTRACT 
Background. To analyse the kinetics of the hepatitis C virus (HCV) and the pattems of 
resistance to interferon alpha (IFN), we assessed the HCV RNA levels early during 
retreatment with high dose IFN in patients who did not respond to standard treatment. 
Methods. Eleven non responders to previous therapy with 3-6 MU IFN three times a 
week were retreated with daily 10 MU. Plasma was sampled at day 0, 1,2,3, 14 and 
28; all samples were prepared within 2 hours and stored at -70°C without thawing until 
analysis. The quantitative HCV RNA level was assessed by the SuperquanFM assay, 
NGI, USA. The Eurohep reference panel, tested blindly, confirmed the linearity of the 
assay with a detection limit for genotype 1 and 3 between 102 and 10' copies/ml. 
Results. All patients showed a fall in viral load between week 0 and week 2 (2.6 log, 
i.e. 99.7%, range 1.3-4.7 log), whereas no fall was detected after week 2. Closer 
examination in 9 patients revealed that all had a dramatic fall in the first 2 days (first 
day 1.8 log, 0.8-3.5; second day 0.8 log, -0.2-1.3), without any significant fall 
thereafter. The calculated half-life of viral decay in plasma was 5 (2-8.9) hours, 
corresponding to a clearance of 2.4 (0.2-13.7) X10" virions per day. Sustained 
responders showed a significant greater fall in viral load in the first day (3.2 log, 2.8-
3.5) than those who did not respond (1.4 log, 0.8-2.1, p=0.001). All three sustained 
responders had undetectable plasma HCV RNA at day 14. 
Conclusion. In patients without a response to standard IFN, the hepatitis C virus has 
a high daily tumover rate similar to that reported in naive patients. Our findings suggest 
that an early clearance of HCV-RNA from the circulation is the key to a sustained 
response, which might be induced in about 25% of these patients by treatment with 
high (10MU) daily doses of IFN. These findings have important implications for the 
concept of treatment of hepatitis C, which should shift its focus from long-term mild 
treatment towards aggressive therapy aiming at a fast viral disappearance within the 
first few days. 
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4.2 INTRODUCTION 
Standard treatment of chronic hepatitis C with interferon alpha 2-b (IFN) 3 mega units 
(MU) thrice weekly (tiw) for 6 months leads to sustained virus clearance in about 15 
percent of patients '. Longer treatment (12-18 months)2 or combination with ribavirin3 
enhances the efficacy mainly by reducing the relapse rate after an initial response. 
However, HCV-RNA still detectable in plasma at 4 weeks of therapy virtually precludes 
sustained virus clearance' .4, pointing to the crucial importance of an early response 
during therapy. In this study with daily high-dose IFN therapy in nonresponders to 
standard-dose IFN, we frequently measured quantitative plasma HCV-RNA levels in 
the first 4 weeks in order to assess the viral kinetics of the hepatitis C virus and to 
relate the pattems of viral decline to response to treatment. 
4.3 MATERIALS AND METHODS 
4.3.1 Study design 
Nonresponders to standard IFN therapy 3-6 MU tiw were offered retreatment by daily 
high-dose IFN at the university hospitals of Rotterdam and Gent Nonresponse was 
defined as lack of normalisation of serum alanine amino transferases (AL T) and 
persistent detectable viral RNA in plasma during IFN therapy. Sixteen patients 
received IFN 10 MU daily for 1 week, followed by 10 MU tiw until week 4 and 3 MU tiw 
until week 24. Treatment was discontinued because of nonresponse if plasma HCV 
RNA was still detectable at week 4 by a qualitative in-house PCR (detection limit 103 
copies/ml). In 5 out of 16 patients no early high-quality plasma samples were available; 
these patients were comparable with those analysed with regard to their pre-treatment 
characteristics. Eleven patients had plasma samples suitable for quantitative HCV-
RNA detection at week 0, 2 and 4 and were included in this analysis. Their mean age 
was 42 years (range 29-61); 8 of them had a genotype 1 and/or a liver cirrhosis, 
known characteristics for low responsiveness to IFN treatment'. Analysis of viral 
kinetics could be perfomned in 9 of 11 patients who had plasma samples available 
during the first 3 days of therapy. Blood was processed within 2 hours and stored 
without thawing at -70°C. 
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4.3.2 HeV RNA detection 
HCV-RNA was quantified at National Genetics Institute, California, USA, by the 
Superquant™ assay, a HCV specific quantitative reverse transcriptase polymerase 
chain reaction, as previously described by Tong et a15. Briefiy, RNA was purified and 
extracted from plasrna samples using guanidiniurn-phenol-chloroforrn followed by 
isopropanolol precipitation. cDNA was made from this DNA using MMLV-RT and 
random primers. In four different reactions of 25, 30, 35 and 45 cycles, the 5'UTR 
region was amplified using two sets of specific primers. The PCR product was 
electrophoresed and hybridized in a Southern blot assay with a digoxigenin labelled 
specific PCR fragment. The bands were electronically scanned and the computerized 
images were automatically compared for size and optical density with the results of an 
internal series of standard RNA with a known number of virions; the result is presented 
as copies per ml plasma. If a samples reached the upper limit of the internal standard 
(5.106 copies/ml) quantification is achieved through 1:10 dilution. The range of the test 
is therefore between 102 _5.107 copies/ml. All samples were tested blindly; the 
Eurohep reference panel6, which is a well characterized dilution series of genotype 1 
and 3, was included as control. The detection limit as calculated from the Eurohep 
results was between 102 and 103 copies/ml for both genotypes, and dilution series 
yielded linear results which were close to expected for genotype 1 and about 0.6 log 
below expected for genotype 3. 
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Figure 1 
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The linearity of the NGI SuperQuant assay was determined using the Pelicheck HCV RNA panel. This 
panel contains assigned HCV RNA dilutions of genotype 1 (gray line) and 3 (black line). These 
assigned values were compared to the calculated line and expressed as HCV RNA copies per ml 
(calculated line). 
The rate of viral clearance (TY,) was calculated according to standard methods?·8, by 
which the half life (T,J2) of viral decay in plasma is calculated for each patient from the 
initial slope (8) of decline between initial viral load and the viral load 24 hours after the 
start of treatment. As the initial decline is exponential by approximation, the half-life 
can be calculated according to T'12 = In(2)/8, where 8 = In (viral 10ad)To - In (viral 
load)T24hours . 
In this calculation the arbitrary value of 102 copies/ml was used for samples with HCV 
RNA below the detection limit of the 8uperquanttm assay, so the half-life calculated in 
those who reached undetectable levels after 24 hours might even be shorter. 
Assuming that the virus is equally distributed in the extracellular water, the initial daily 
clearance rate can be estimated from the T'I2, the concentration of viral particles in 
plasma and the extracellular fluid volume for each patient according to the equation: 
initial daily clearance = Veo x ColT'l2 (V'" = extracellular volume in litres, Co = pre-
treatment viral concentration in copiesllitre and T
'
J2 = half-life in days). 
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4.4 RESULTS 
The characteristics of the 11 patients with suitable plasma samples for HCV-RNA 
detection are listed in table 1. All patients showed a drop in the level of viraemia 
during the first 2 weeks. The mean decrease observed was 2.6 log (99.7%) with a 
range of 1.3-4.7 log. Between week 2 and 4 the fall in viral load was minimal (mean 
0.2 log, range -0.7-1.4). Nine patients had day 1, 2 and 3 samples available; their 
mean reduction in viral load was 1.8 log (0.8-3.5) at day 1,0.8 log (-0.2-1.3) at day 
2 and 0 log(-0.7-0.5) at day 3 (Fig 2A). No further drop in viral load was observed 
between day 3 and day 28, mean -0.2 log, range -1.9-0.7 (Fig 2B). Three out of the 
11 patients (27%) became sustained responders (ALT normal and HCV-RNA 
undetectable 6 months after end of treatment). All three sustained responders had 
undetectable HCV-RNA at day 14. In the group of 9 patients with samples available 
at day 1-3 the fall in viral load at day 1 in the two sustained responders was 
significantly greater (2.8 and 3.5 log respectively) compared to the seven others 
(mean 1.4 log, 0.8-2.1, p=0.001). The follow-up period for the sustained responders 
is more than 5 years. The calculated mean half-life of viral decay in plasma was 5 
hours (range 2.0--8.9); the estimated half-life in the two responders who could be 
analysed was 2.6 and 2.0 hours when the calculation of undetectable samples was 
based on the arbitrary level of 102 copies/ml. Therefore the half-life is only a minimal 
estimate and may even be lower. The estimated initial daily clearance rate ranged 
between 0.2-13.7.10" virions per (mean: 2.4.10"). 
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Figure 2 A and B 
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Fall in viral load in patients with chronic hepatitis C following JFN 10 MU daily for at least 5 days and 
thereafter 10 MU thrice weekly. The mean drop in viral load in the first day was 1.8 log (0.8-3.5). 
Between day 1-2 there was a drop of 0.8 log (..0.2-1.3), whereas no drop in v'lral load was found 
between day 2-3 (0 Jog, range: -0.7-0.5). In total, the drop in viral load was 2.5 Jog between day 0-
3 and between 0 log day 3-28. 
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Table 1 Baseline characteristics and viral dynamics, of patients treated with interferon 10 MU daily. 
Patient genotype cirrhosis age pre-treatment decrease in viral estimated initial T 1/2 (hours) outcome 
(years) viral level load: day 0-2 clearance rate to treatment 
(coples/ml) (log) (copies/day) 
1b yes 61 4.7.10' 2.3 3.10" 6.0 NR 
2 1b na 29 0.5.10' 1.8 0.2.10" 8.9 NR 
3 1b yes 60 5.0.10' 2.6 3.4.10" 5.6 NR 
4 1b na 52 5.2.10' 1.1 3.6.10" 5.6 NR 
5 4 no 35 6.0.10' 2.5 4.1.10" 5.6 NR 
6 4 yes 43 1.8.10' 1.9 1.5.10" 4.5 NR 
7 1b na 50 12.2.10' 2.8 13.7.10" 3.5 NR 
8 1a na 30 0.3.10' 3.5 0.6.10" 2.0 SR 
9 3 na 37 5.2.10' 3.5 7.7.10" 2.6 SR 
10 1b na 31 2.9.10' n.a. n.8. n.8. NR 
11 3 na 34 2.8.10' n.8. n.a. n.a. SR 
Range: 29-61 0.3-12.2.10' 1.1-3.5 0.2-13.7.10" 2-8.9 
Mean: 42 2.8.10' 2.4 2.4.10" 5.0 
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4.5 DISCUSSION 
Until recently, the hepatitis C virus was considered to have a low turnover rate and 
response to antiviral treatment was thought to occur gradually over several weeks. In a 
recent consensus at the National Institutes of Health of the USA, it was recommended 
to evaluate the initial response to therapy by testing HCV-RNA after 3 months"' 
Because of these concepts on the dynamics of hepatitis C virus infection, most of the 
large treatment studies have focussed on enhancing efficacy by prolonging therapy up 
to 18 months2. In this study we found an ultrarapid HCV-RNA clearance, with a mean 
half-life of 5 hours during the first day of 10 MU IFN therapy. In 1996 Zeuzem 
described an exponential decline of HCV-RNA with a mean half life of approximately 2 
days; however, samples were not taken daily and patients received a lower dose of 3 
MU IFN given three times per week. With a higher dose of 6 MU IFN given daily 
Yasui 'o observed a mean T'12 of 8 hours. Recently Lam et al8 described a dose-
dependent effect of IFN in clearance of HCV genotype 1 patients, naive for IFN. With 
one injection of 10 MU IFN and by use of the bONA assay (detection limit 3.5.105 
copies/ml), they found a mean half-life of 7.2 hours and an estimated daily clearance of 
3.7.10" particles per day. In our group of nonresponders to previous standard dose 
IFN we found similar results as Lam et al. with the validated sensitive Superquanttm 
assay (detection limit 102 -1 03 copies/ml). A partial blockade in viral production induced 
by a sub-optimal dosing of IFN can cause an overestimate of the half-life because of 
the resulting sub-optimal decrease in viral load. The studies by Zeuzem, Yasui and 
Lam in naive patients together with our current study in non responders suggest that 
IFN 10 MU per day might block virion production more completely than IFN 3-6 MU. 
Interestingly, the two sustained responders showed the shortest half-life of viral decay 
in plasma (2.6 and 2 hours, table 1). After the initial very fast decline in viral load in the 
first two days in all patients, no further decline is seen thereafter. Lam et al. also found 
a rise in HCV-RNA about 48 hours after the IFN injection and proposed that daily 
dosing might help to continue the decline in HCV-RNA. However, we found this same 
rise in HCV-RNA after 48 hours while 10 MU IFN was continued daily. The reason for 
lack of a further fall in viraemia around 48 hours is unclear; it might be related to 
selection of IFN resistant virions or down regulation of IFN receptors and intracellular 
escape. Further studies on resistance need to focus on this early period. 
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Therapeutically, this study adds further evidence that non responders to a standard 
dose IFN can benefit from high dose treatment. This conclusion might however not be 
generalized for all nonresponders because in this pilot study none of the sustained 
responders had cirrhosis and only one had a genotype 1. 
In conclusion this study reveals a very rapid replication of the hepatitis C virus with a 
frequent development of res',stance within 48 hours after initialisation of treatment. The 
results of this study suggest that the key to a sustained response is an early clearance 
of HCV-RNA from the circulation. 
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Chapter 5 
5.1 VIRAL KINETICS IN CHRONIC HEPATITIS C 
Lam et al. reported an exponential decline in viral load after one injection of Interferon 
in hepatitis C, genotype 1 positive patients, naive for Interferon 1. A dose dependent 
relation was found with the maximal drop in viral load after one injection of 10 MU 
Interferon. An exponential decline in viral load was described for the first 2 days after 
injection, followed by a decrease in the slope of viral decline after day 2. Based on 
these results prolonged therapy with 10 MU was suggested to continue this rapid v'lral 
decline. We conducted a study in which we re-treated nonresponders to previous 
standard dose interferon. Patients received 10 MU IFN daily for one week, followed by 
10 MU thrice weekly thereafter till week 4. We collected the same early plasma 
samples as Lam et al. (pre-treatment and after 24, 48 and 72 hours) as well as later 
samples after 2 and 4 weeks of treatment. Samples were tested with a sensitive, 
validated quantitative PCR assay for HCV RNA (Superquant,m, National Genetics 
institute, LA, detection limit between 102_103 copies/ml). We calculated the half-life and 
the production rate of the hepatitis C virus from the results of exponential decline, 
observed within the first days of treatment. To compare our data with those of Lam et 
aI., we restricted our analysis to the six patients with genotype 1. During the first two 
days, a steep decline in viral load was observed similar to that reported by Lam et al. 
However, the loss of viral decline after 2 days which was attributed by Lam et al. to the 
weaning of the effect of the single dose of Interferon was also observed in five out of 
six patients despite continuation of treatment with daily high doses of interferon. The 
drop in viral load proved to have 2 phases, first an exponential rapid decline from day 1 
till day 3 followed by a much slower second phase of viral decline from day 3 onward. 
The slope (a) of the viral decline can be used to calculate the half-life (T'12 ) according 
to T,12= a/log2. The mean half-life for these 6, genotype 1 patients was 6.7 hours for 
the initial phase (figure 1, T
'J2 alpha), with a range between 2-13 hours. This was 
followed by a much slower elimination in four out of 6 patients with a half-life of 
approximately 400 hours (figure 1, T
'
J2 beta) and a range between 244-573 hours. In 
2 patients no half-life of the second phase (T'12 beta) could be calculated; one patient 
had a very fast drop in v'lral load and became HCV RNA negative after 24 hours and 
remained a virological sustained responder, and one patient showed a very Slight rise 
in viral load between day 2 and day 28. If we examine the observed drop in viral load, 
the decline ',n viral load can not be described by a simple exponential model but fits 
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into a 2 ,d order kinetic model, designed to describe the decline in concentration for 
substances that are dissolved in 2 compartments with 2 different elimination rates. 
Based on the initial half-life of about 7.6 hours and the average pre-treatment viral load 
of about 3.107 copies/ml, it can be calculated that if a viral load of < 1 copy/ml is to be 
reached a high dose induction treatment would be needed for at least 7 days. This 
means that we need at least 20 x T'12 alpha before we reach HCV RNA negativity 
based on the initial fastest decline. However, prolongation of high dose interferon up 
to 1 to 2 weeks is probably not the simple solution for patients that fail to reach very 
low (below 100-1000 copies/ml) viral levels after the first 2 days of daily high dose 
treatment because of the appreciable change in elimination rate. If we consider the 
much longer half-life of the hepatitis C virus observed after day 2, much longer 
treatment is needed to reach HCV RNA negativity. Based on the T1I2 beta of around 
400 hours and an average viral load of 20000 copies/ml after the first 2 days of 
treatment, a prolonged therapy of about 250 days is needed, this equals 15 x T'12 beta. 
Long continued treatment in combination with a high dose induction treatment appears 
to be the best solution until we understand the biology of virus clearance and ways to 
modulate it. 
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Mean drop in hepatitis C viral load observed between day 0 and week 4 in 6 chronic hepatitis C 
patients, infected with genotype 1, Alpha: slope of viral decline observed between day 0 - 2, Beta: 
slope of viral decline observed between day 2 - 28. 
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6.1 ABSTRACT 
Background. Patients with HCV genotype 1 infection are resistant to standard 
interferon therapy. We used a mathematical model to estimate the duration of daily 
therapy necessary to maximize the number of patients achieving viral negativity 
before 12 weeks of therapy. 
Design. Patients from a study to determine HCV RNA reduction over 4 weeks using 
3MU, 5MU, or 10MU of alpha interferon daily plus ribavirin were compared with a 
group receiving alpha interferon 3MU tiw. All patients had HCV genotype 1 infection 
and baseline serum HCV RNA levels> 1 million copies/ml. HCV RNA was measured 
at days 0, 0.5, 1, 3, 5, 7, 10, 14, 17, 21, 24 and 28. Each measurement was log 
transformed and the means for each group computed. Using the mean kinetic data, 
linear regression and 95% confidence intervals were calculated and projected to the 
lower limit of detection of serum HCV RNA in order to estimate the treatment time 
needed for each treatment regimen. After day 28, patients continued therapy with 
interferon alpha 2b 3 million units tiw plus ribavirin. 
Results. By extending the linear regression and prediction interval lines, the 
estimated time to negativity was greater than 12 weeks for the standard interferon 
group, 42- > 84 days for the 3MU interferon daily plus ribavirin, 39-60 days for 5MU 
interferon daily plus ribavirin and 25-45 days for the 10MU interferon daily and 
ribavirin group, respectively. 
Conclusion. Thus, the use of a predictive model based on log transformation and 
linear regression of the early HCV RNA response suggests daily doses of 5 or 10 
million units of interferon plus ribavirin will be theoretically necessary for longer than 
4 weeks to maximize the number of patients who clear virus by 12 weeks of therapy. 
This model may be useful in predicting response in groups of patients receiving other 
therapies. 
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6.2 INTRODUCTION 
Chronic hepatitis C infection is a slowly progressive disease that can lead to cirrhosis 
andlor hepatocellular cancer over a period of 10 to 20 years. ' In the United States, it is 
estimated that nearly 4 million individuals are infected (1.8% of the population) and that 
there are approximately 30 thousand new cases of acute hepatitis C annually.' 
Estimates indicate that there are eight to ten thousand HCV-related deaths annually, 
and that this number is expected to triple in the next two decades. Currently, hepatitis 
C is one of the leading causes of chronic liver disease in the United States, and the 
most common indication for liver transplantation.3 
The rationale for induction therapy in chronic hepatitis C infection include the 
suboptimal response rates observed with conventional alternate day interferon 
monotherapy, the large viral burden and high rates of viral turnover.'"" Also, an acute 
dose response has been reported with higher daily doses of interferon in chronic 
hepatitis C, and a biphasic exponential viral decline has been described in chronic 
hepatitis C virus infection during therapy.5-? In addition, most patients who achieve a 
sustained virologic response to antiviral therapy do so early during treatment, (in 
general before week 12), 9-13 and a greater than 3 log reduction in serum HCV RNA 
early during therapy has been reported to be a good predictor of eventual sustained 
response.14 Early clearance of hepatitis C virus may also theoretically prevent the 
development of resistant quasispecies.' 5-17 Taken together, these facts indicate that 
induction therapy with increased andlor daily interferon dosages may provide potential 
benefit in terms of long-term sustained response, although there is currently little 
prospective data to support this concept. 
Induction therapy with interferon alone or in combination with ribavirin may thus 
provide a potential therapeutic strategy that may improve sustained response rates in 
individuals who are historically difficult to treat. These include patients infected with 
HCV genotype 1, and those with high viral load. 
The aim of this study was to attempt to estimate the duration of daily combination 
therapy that would theoretically be necessary to achieve the maximum number of 
patients that have undetectable serum viral levels by 12 weeks of therapy. 
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6.3 MATERIALS AND METHODS 
We collected data from a prospective 4-week trial of viral kinetics in 65 patients 
receiving initial treatment with interferon plus ribavirin. There were four groups of 
patients included in the study. The baseline demographics of the 4 patient groups are 
shown in table 1. The groups were well matched according to these baseline 
characteristics. There were 13 to 19 patients in each group. For the initial four weeks 
of this study the patients in these 4 groups received either interferon 3 million units 
(MU) subcutaneously tiw, daily doses of 3 MU of interferon plus ribavirin, 5 MU of 
interferon daily plus ribavirin, or 10 MU of interferon daily plus ribavirin, respectively. 
ribavirin was given orally in divided doses of 1,000 mg (weight < 75 kg) or 1,200 mg 
(weight> 75 kg). 
All patients had compensated liver disease and documented chronic HCV infection by 
hepatitis C antibody testing, histologic findings consistent with chronic hepatitis C and 
the presence of serum HCV RNA. Clinical, laboratory, and histologic evaluation 
excluded other causes of chronic liver disease. The Institutional Review Board of each 
participating center approved the protocol. The patients had not received prior 
treatment for their chronic hepatitis C infection, and all were infected with HCV 
genotype 1, and had high viral load prior to therapy defined as greater than 1 million 
copies/mL. None of the patients had histologic findings compatible with cirrhosis. 
Although these patients were not matched at enrolment, by virtue of the fact that they 
were chosen according to these characteristics, they were relatively homogenous. 
6.3.1 Detection of Serum HCV RNA 
Serum samples were collected frequently within the first 4 weeks of treatment (t=O, 0.5, 
1, 3, 5, 7, 10, 14, 17, 21 and 28 days after treatment initiation). A quantitative 
multicycie RT-PCR assay was performed at the National Genetics Institute (NGI, Los 
Angeles, California), as previously reported.18 The sensitivity of this assay is 100 
copies/ml with an intra sample coefficient of variation of 26%. All samples were tested 
blinded and in duplicate. 
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6.3.2 Hev Genotype Determination 
HCV genotyping was carried out on biotin-labelled PCR products by hybridization to 
oligonucleotides directed against the variable region of the 5' UTR, and then 
immobilized as a parallel line on membrane strips (line Probe Assay, InnoliPa HCV II, 
Innogenetics, Belgium) (19). 
6.3.3 Statistical and Mathematical Modelling 
The SPSS software package (SPSS Inc., Chicago) was used to perform linear 
regression of the log-transformed data from these patient groups. We log transformed 
the viral load data on each patient, calculated the geometric mean for each treatment 
group, and created linear regression lines. (Because viral loads fall many orders of 
magnitude when effective therapy is given, log transfonmation is used so that data at 
high and low viral loads have more equivalent weight in the linear regression analysis.) 
First, we included data from both the early first phase of viral decline, as previously 
reported5-7 to observe the linear regression of phase one and two combined. Second, 
we included only data from the second phase (viral load data after 48 hours after 
treatment initiation) to test the hypothesis that the slope of the second phase alone can 
be used to predict treatment duration until viral negativity is reached, and to test 
whether the second phase of viral reduction follows an exponential decline as 
previously described.s 
Using this software, 95% confidence intervals were also calculated for these linear 
regression lines for the four groups. Mathematically, the model is very simple: y = at + 
b, where t is treatment time, y = log transfonmed viral load data, a = the calculated 
slope of viral decline and b = log transfonmed viral load at t=O. The linear regression 
and prediction interval lines were extrapolated beyond the four weeks of the study to 
the lower limit of detection of the HCV RNA assay (less than 100 copies/mL). 
We made two assumptions that we felt were theoretically reasonable and necessary. 
First, that the data would follow a biphasic exponential decline or equivalently that the 
log transformed data would follow two straight lines consistent with published data.7 
Second, that projecting the line corresponding to the second phase to the y intercept or 
level of viral detection will provide an estimate of the duration of daily therapy 
necessary to achieve viral negativity. Since induction therapy ended at 4 weeks, this 
assumption is equivalent to assuming that the rate of HCV decline will remain constant 
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when patients are switched to maintenance therapy. If the rate of decline slows, such 
as if there was a third or multiphasic response, then our estimates will be minimal 
estimates of the time needed to reach negativity. 
6.4 RESULTS 
The four patient groups were well matched prior to treatment for age, sex, AL T values, 
HCV RNA concentrations and severity of i"lver disease (table I). The ind',vidual 
regression plots with 95% prediction intervals indicated are shown in figure a-d for the 
4 treatment regimens. The correlation coefficient (r) for the combined log transformed 
data is high for the daily 5 MU and daily 10 MU treated groups (.92), but much lower 
for the daily 3 MU (.72) and 3 MU tiw (.52) group. Combining the individual plots (table 
2) shows that the estimated time to reach viral negativity is progressively shorter when 
the treatment dosage is increased. Only the treatment schedules using 5 MU and 10 
MU interferon daily show a 95% prediction of viral negativity before week 12. The 
prediction interval for the 3 MU three times weekly interferon monotherapy group was 
too wide to make a reasonable prediction of the estimated time to reach viral negativity 
in this group, consistent with the poor clinical experience with this dosing in these 
patients. 
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Figure 1 A-D 
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Figure 1 A-O: Represents the calculated linear regression lines and 95% confidence intervals for the 
patient groups that received interferon 3MU tiw (A), interferon 3MU daily plus ribavirin (B), interferon 
5MU daily plus ribavirin (C) and interferon 10MU daily plus ribavirin (0) for the first 4 weeks of therapy 
respectively. The data were calculated using SPSS software of the log-transformed viral load data from 
each patient, the geometric mean for each treatment group at each time point, and then we created 
linear regression lines and confidence intervals. Data shown for each of the groups includes both phases 
of viral decline. 
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Table 1: Baseline Characteristics 
3 MU IFN 3 MU IFNIQD 5 MU IFNIQD 10 MU IFN QD 
TIW + Riba + Riba + Riba 
N 13 15 18 19 
Age (years) 48 41 45 41 
Sex (MIF) 815 1114 1117 1415 
AlT (lUlL)' 101 115 92 100 
HCVRNA' 3.9x10' 3.6x10' 5.1 x 10' 4.2 x 106 
"AL T - normal range 0- 45 lUlL 
bHCV RNA by RT-PCR, expressed as copies per ml serum. Detection limit < 100 copies/mi. 
Table 2: Estimated time to reach viral negativity using combined data from the first and 
second phases 
3MU IFN 3 MU IFNIQD 5 MU IFNIQD 10 MU IFN QD 
TIW + Riba + Riba + Riba 
Log Reduction at -1.06 -2.8 -3.1 -3.7 
week 4 (observed) 
Negative by 4-wk 0113 (0%) 3115 (20%) 5118 (28%), 7119 (37%),' 
2-109 reduction at 4-wk 2113' 9115' 12118' 15119' 
(99%) 
(15%) (60%) (66%) (79%) 
Linear regression (r) .52 .76 .92 .92 
Estimated time to >84 65 52 36 
negativity (days) 
95% CI (days) 78->84 42->84 39-60 25-45 
: p<0.05 (3 MU TIW vs 5 MU QO and 10 MU QO) 
': p<O.05 (3 MU QO vs 10 MU QO) 
': p<O.05 (3 MU TIW vs 3 MU QO, 5 MU QO and 10 MU QO) 
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Results at week four of treatment also showed a faster decline in viral load with 
increased interferon dosage (Table 2). A significant difference in viral negativity at 
week 4 was observed between the 2 high dose (5 and 10 MU) daily dosing groups and 
the standard 3 MU IFN tiw group. and between 3 MU IFN plus ribavirin daily and 10 
MU IFN plus ribavirin daily (Table 2). 
The data for the second phase only (regression and confidence interval) did show that 
viral reduction followed an exponential decline and a dose -dependent response only 
for the daily interferon groups. Again a significant difference was observed in the drop 
in viral load within the observed 4 weeks for the daily 3 MU interferon plus ribavirin 
group compared with the daily 10 MU interferon plus ribavirin group ( P = 0.025) (Table 
3). 
Table 3: Estimated time to reach viral negativity using only data from the second 
phase of viral decline (day 2-day 28) 
3 MU IFNIQD SMU IFNIQD 10 MU IFN QD 
+ Riba + Riba + Riba 
Log reduction at wk 4 -1.46-- -1.63 -2.25' 
Linear regression (r) .96 .95 .95 
Estimated time to 57 52 37 
negativity (days) 
Days (CI) (52-64) (46-58) (33-42) 
95% CI (days) 
.., p<O.05 3 MU IFN/QO + RJba vs 10 MU IFN aD + Rlba 
All other comparisons not significant 
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6.5 DISCUSSION 
With the introduction of combination therapy with interferon alpha-2b plus ribavirin. the 
chance of achieving a sustained virologic response has dramatically increased for 
chronic hepatitis C patients. However, patients with genotype 1 infection and a high 
viral load (defined as higher than 1-2 x 10' copies/ml) still have a limited chance of 
achieving a sustained response."·20.21 Even though not all patients that become 
sustained responders show a rapid disappearance of HCV RNA," one of the strongest 
predictors of a sustained viral response in the majority of patients is still the early 
(within 12 weeks) clearance of serum HCV RNA. This rapid HCV RNA clearance will 
not be reached in the majority of HCV genotype 1 patients with a high viral load. Thus, 
improved treatment options for these patients are necessary. 
To assess the efficacy of higher dose interferon strategies on the initial response we 
used a linear regression model that described the overall change in viral load for 
groups of patients. Various models have previously been used to describe the decline 
in viral load during treatment',·,22 To compare the efficacy of different treatment 
regimens within a group of standardized patients we calculated the geometric mean 
value of the viral load in each group at each time point. Linear regression of the 
geometric means for each time-point of HCV RNA measurement provided a line that 
described the average slope of viral decline in each group of patients. Since we only 
included genotype 1 infected patients with high viral load (although the patients were 
not matched for other variables), the differences in the calculated slopes of viral 
decline are most probably attributable to the differences in treatment that these groups 
received. 
We propose that both the rapid and the slower phase of viral decline"? are important 
for reaching viral negativity: a patient with an extremely large first phase viral decline 
will reach undetectable levels of HCV RNA much earlier than someone with a minimal 
first phase viral load decline, assuming both have the same second phase of viral 
decline. Since it is rare for a patient to reach viral negativity during the first phase, the 
slope of the second phase will ultimately determine if someone reaches negativity. 
Since the second phase generally includes all data from the second day of treatment 
onward, use of only second phase data has been shown to provide a good prediction 
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for viral negativity of individual patients at 12 weeks? and thus should be sufficient to 
determine the expected duration of daily therapy to reach viral negativity.s 
The linear regression model that we have proposed can be used with the combined 
data of both phases or with data of the second phase alone. In our study, two 
measurements of HCV RNA before 2 days of treatment (0.5 and 1 day) and 8 points of 
the slower second phase were included in the overall model, leading to a prediction 
interval that did not differ significantly from an evaluation including only the second 
phase. Both analyses showed a more rapid viral decline with higher doses of 
interferon. Whilst combining both phases in the predictive model produced a more 
conservative estimate of the interval required to clear HCV RNA, data obtained using 
the second phase only may be more clinically relevant, and more readily available to 
practicing clinicians. 
The first phase of viral decline has previously been shown to be exponential and 
dose dependent.' This study is the first to show a clear dose-dependent and 
exponential decline in viral load also during the second phase of viral decline. A 
significantly faster mean second phase slope was observed, even in this small study, 
in the group treated with 10 MU interferon plus ribavirin daily than in the group 
treated with 3 MU interferon plus ribavirin daily. This model - when applied to our 
data - strongly suggests a dose dependent efficacy of interferon in genotype 1 
patients and clearly shows the inefficacy of interferon monotherapy when given as 3 
million units IFN thrice weekly for this group of patients. Since this study was 
designed to show differences between different treatment schedules, it is not clear 
that this method for determining the necessary daily treatment period can be used for 
individual patients. This would require further prospective evaluation. 
A large number of patients reaching early viral negativity theoretically allow for a high 
rate of end of treatment response, provided that breakthrough does not occur when 
interferon dosage is decreased. Unfortunately, this study used data from a 4-week 
treatment schedule and therefore the effect of a faster viral decline on sustained 
response could not be examined. Within the observed 4 weeks of the study the 
previously reported biphasic decay in viral load? was confirmed in our study. Whilst the 
possibility exists that a further slower phase of viral decline occurs after these initial two 
phases observed in many studies, to date there is no published data to support the 
possibility of a multiphasic decline beyond this period. Because our study was limited 
83 
Chapter 6 
to the first 4 weeks of therapy we cannot rule out that the rate of viral decline slows or 
is altered at later time points. If this latter scenario applies, our estimates would be 
minimal estimates of the time needed to reach negativity, and thus may not predict 
long temr outcome after therapy. 
The failure of the standard tiw regimen to achieve negativity before week 12 is 
consistent with the poor response of this regimen in the genotype 1 patient population. 
However, the 95% prediction interval of the 3 MU daily IFN also fell outside the 12 
week ''window'' suggesting that th',s regimen, even though ',t appears much better than 
the standard tiw regimen, will be insufficient to maximize the number of patients 
achieving viral negativity early in therapy. These daily dose regimens may be 
superseded by the introduction of newer, longer acting forms of interferon and thus will 
likely not be used extensively clinically. However, this model could be used to 
determine the initial doses of new therapies to maximize the chances of success. 
What are the implications of this study for the clinician? The most important factors 
identified to influence response to treatment with interferon plus ribavirin in two large 
multicenter studies were HCV genotype and viral load."·21,23 Other factors including 
the degree of histologic fibrosis, gender, body weight and age were less predictive of 
response, but also identified by stepwise logistic regression analysis."·21,23 In a 
clinical setting with an individual patient, information regarding HCV genotype is 
important, since it is generally recommended that genotype non-1 infected patients 
require only 24 weeks of combination therapy, and those with genotype 1 receive 48 
weeks. Because of the fiuctuations in viral burden seen in untreated patients and the 
numerous HCV RNA assays, which are currently not standardized and have variable 
sensitivities, viral load has a more limited clinical value. It is thus difficult to make 
recommendations regarding outcomes according to viral load reductions during 
therapy and baseline values. Because the majority of chronic hepatitis C patients 
have an unfavourable profile and are in need of more effective therapy, we have 
attempted to show in this study that for these patients, the dose of interferon when 
combined with ribavirin and the dosing interval are also factors which can influence 
early clearance of serum HCV RNA. 
In conclusion, after log-transformation of viral load data, a simple linear regression 
analysis can be used to compare the kinetics of viral decline between treatment 
strategies. Interferon monotherapyat .a dose of 3 MU tiw is predicted to be insufficient 
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to lower the viral load below the limit of detection within 12 weeks in genotype 1 
patients with high pretreatment viral load. Based on extrapolation of data obtained 
during the first four weeks of treatment, daily dosages of 5 or 10 MU IFN daily plus 
ribavirin will be necessary to reach viral negativity in the majority of these difficult to 
treat patients. None of the treatment schedules caused such a rapid viral decline that 
daily treatment could be stopped before 4 weeks. 
New stUdies should focus on higher doses of daily interferon or longer acting interferon 
preparations andlor the combination of interferon and ribavirin in order to improve the 
low response rate in genotype 1 patients. Prospective studies to assess the efficacy of 
initial daily interferon therapy plus ribavirin for 24 weeks are currently in progress. The 
simple model used in this study might be helpful in comparing future treatments in 
order to evaluate the differences in efficacy for this difficult to treat patient population. 
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7.1 ABSTRACT 
Background. Hepatitis C viral kinetics show an increased antiviral effect of higher 
than standard interferon dosages and of daily treatment schedules. Since interferon 
has a short half-life, twice-daily administration of interferon may be even more 
effective. 
Methods. We evaluated HCV kinetics in daily versus twice-daily high dose interferon 
(lFN) therapy in combination with ribavirin in 24 difficult to treat patients. Patients 
were randomised to 10 MU IFN daily or 5 MU twice-daily for 4 weeks. 
Results. Interferon efficacy (e) was similar and very high for both groups (range 
99.83-99.97%). Clearance of infected cells (beta phase) tended to be slightly faster 
for patients on 5 MU bd (T1/2 70 vs 90 hrs, ns). Clearance of infected celis was 
strongly related to initial viral load (T1/2 103 vs 53 hrs, p=0.002, for above versus 
below 2x106 copies/ml). An additional phase with a temporary rise in viral load was 
observed between the alpha and the beta phase. 
Conclusion. daily high induction dose is associated with nearly complete inhibition of 
viral replication even in difficult to treat patients. A twice-daily schedule did not lead to 
further improvement. Clearance rate of Infected celis was significantly correlated with 
initial viral load. 
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7.2 INTRODUCTION 
Viral kinetic studies have demonstrated the increased antiviral effect of higher than 
standard dosages of interferon and of daily versus thrice weekly treatment 
schedules. The anti-viral effect can be described by a fast initial decline, reflecting 
the efficiency of inhibition of viral replication, and a slower second phase presumably 
related to the clearance of infected cells. Since interferon has a short half-life of only 
about 8 hours, twice-daily administration of interferon may be more effective. 
With standard doses of interferon, even in combination with ribavirin, about 50% of 
patients do not achieve a sustained remission 1·". These difficult to treat patients are 
mainly identified by the pre-treatment characteristics genotype 1 virus infection, high 
viral load and presence of cirrhosis. In this group of patients we analysed whether 
twice-daily treatment could increase the inhibition of viral replication compared to 
daily dosing. In addition, the effect on the other parameters of the viral dynamics 
were studied, especially the effects on the clearance of infected cells, using both 
individual as well as group-based methods. 
7.3 MATERIALS AND METHODS 
7.3.1 Patients 
Twenty-four difficult to treat chronic hepatitis C (detectable HCVRNA for longer than 
6 months) patients were included in this trial; 21 with a previous non (-sustained*) 
response and 3 without previous treatment but having a liver cirrhosis. Standard 
exclusion criteria were applied with regard to contraindications to interferon and/or 
ribavirin, immune suppression, concomitant other causes of liver disease, other 
severe diseases, or clinical signs of decompensated liver disease (ascites, variceal 
bleed, encephalopathy) 4 However, the threshold for bilirubin level and platelets 
count was adjusted to twice the upper limit of normal and 50.000 /mm3, respectively; 
this adjustment was made to allow inclusion of patients with more advanced liver 
disease, the group which needs treatment the most. 
" Non (-sustained) response: nonresponse (no HCV RNA negativity during treatment) or relapse (HCV 
RNA negativity during treatment followed by a relapse of HCV RNA after treatment) 
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7.3.2 Randomization 
After informed consent was signed, consecutive patients were assigned a treatment 
schedule based on a computer-generated list by an independent person of the 
research co-ordinating centre. 
7.3.3 Treatment schedule 
After a first induction dose of 10 MU, group one continued with daily 10 MU IFN for 4 
weeks while group 2 continued with 5 MU every 12 hours for 4 weeks **. Ribavirin 
was given twice daily orally in d',vided doses of 1,000 mg (we"ght < 75 kg) or 1 ,200 
mg (weight'" 75 kg). 
7.3.4 Measurement of serum HeV RNA 
Blood samples were taken frequently during the first 4 weeks (T= 0, 8, 24, 32, 48, 56, 
72, 96 hours and at week 1,2,3 and 4) of treatment. Blood was collected in (PPT) 
tubes (Bacton-Dickerson) which were centrifuged directly after collection in order to 
minimise RNA breakdown "-
After centrifugation, the tubes were transported within 72 hours to the central virology 
department where plasma was aliquotted in separate tubes that were stored at -
80°C. Viral load was quantified by NGI (Culver City, Los Angeles, CA, USA), using a 
quantitative multi-cycle RT-PCR assay 6. The sensitivity and linearity of the assay 
has been validated for genotype 1 and 3 with the use of the Eurohep standard series 
7. Qualitative HCV RNA determination was performed in-house, using the Roche 
Cobas Amplicor assay. The lower detection limit for both assays was similar and less 
than 103 copies/ml. 
7.3.5 Mathematical modelling and biostatistics 
We analysed the data according to the bi-phasic mathematical model of Neumann et 
al. 8, using a biostatistical mixed model with random effects (Macro NLiNMIX in SAS 
6.12 software). The benefit of this modelling technique is that the entire data set can 
be analysed and that an overall population curve can be generated (Figure 1). Since 
this technique can be applied to an entire group, it is possible to analyse the effect of 
patient characteristics or treatment modulations on the viral kinetics parameters 
(Figure 2). 
**AII patients completing 4 weeks of treatment were rolled over in an associated study to determine 
the durability of an early virological response during maintenance therapy and after stopping 
treatment. 
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In addition, the viral dynamic data were calculated for each individual as described 
previously by Neumann using Proc NLiN in SAS 6.12. 
In accordance with guidelines recently proposed by a European collaborative group 
on viral dynamics (Ditto-HCV workshop, Paris 1999), patients were only included for 
viral dynamics analysis if a minimum of quantitative HCV-RNA data were available 
(T=O, at least one value within the first 2 days of treatment and at least 3 quantitative 
measurements between day 2 and day 28). Differences between pre-treatment 
characteristics (Kruskal-Wallis test) and HCV RNA negativity at week 4 (Fisher-exact 
test) were calculated with SPSS version 9.0 software. 
Figure 1 Estimated viral decline using the viral load data of all patients 
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The closed line is the mathematical estimation of the overall viral decline, based on the mathematical 
model of Neumann et at (1998) 8 and a new statistical analysis method (macro NLiNmix in SAS 
software). All actual measured viral load data are showed as dots. Viral load data below the detection 
limit of the quantitative assay are displayed as dots at the level of the detection limit (102 copies/mI). 
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Figure 2 
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Estimated viral decline can be calculated for sub groups separately by using a statistical mixed model 
analysis. In this figure the separate lines for group 1 (receiving 10 MU IFN/daily; 
striped line) is plotted together with the estimated decline for group 2 (receiving twice daily 5 MU IFN; 
solid line). No significant difference in viral decline is present between these separate groups (see also 
table 3) 
7.4 RESULTS 
The pre-treatment patient characteristics are shown in table 1. As shown, both 
groups were balanced according to baseline patient characteristics. Most (21/24) 
patients were non-sustained responders to previous interferon treatment. Six out of 
24 patients (25%) fitted our criteria of more advanced liver disease, having elevated 
bilirubin levels andlor platelet counts below 100.000 Imm3 . 
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Table 1: Pre-treatment patient characteristics. 
Group All patients 10 MU/d 5 MU/b.i.d 
Number 24 12 12 
MaJe 17 8 9 
Age mean 46.5 43 50 
median 47.5 44 50.5 
Previous NRireJapse/naYve 14/8/2 71411 7/4/1 
ALT baseline (x ULN) mean 2.7 2.6 2.9 
median 2.6 2.7 1.9 
Pre-treatment HCV RNA" mean 1.5x106 8.3 x 105 2.6x106 
(copies/ml) median 2.6 x 106 3.0 X 106 2.2x106 
Genotype 1 11 7 4 
Cirrhosis 11 4 7 
Mean and median viral load is calculated on the log-transformed viral load data 
Out of the 24 patients, two stopped early after treatment initiation «10 days): one 
because of non-compliance and one because of cardiac complains. Out of the 22 
patients that completed the first 4 weeks 17 (77%) became HCV RNA negative by 
qualitative PCR (Table 2). The number of patients that reached PCR negativity within 
4 weeks did not differ between the 2 groups of therapy. Genotype 1 and cirrhosis 
were patient characteristics that appeared to correlate negatively with HCV RNA 
response at week 4, but the only pre-treatment factor that correlated significantly with 
viral response was a low viral load (less than 2 x 10' copies/ml). 
Viral dynamics parameters could be calculated in 20 patients as two patients reached 
HCV RNA negativity within 24-48 hours after treatment initiation, providing 
insufficient viral load measurements for viral dynamics analysis. 
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All 20 evaluable patients showed a fast drop in viral load between 8 and 32 hours 
after treatment initiation followed by a second slower phase in viral decline. Analysis 
of the viral dynamics showed a high interferon efficacy in all patients (range: 99.83 -
99.96%). Patients with unfavourable baseline characteristics (cirrhosis, genotype 1 
infection, high viral load or previous nonresponse) had a similar rapid first phase viral 
decline as the others. However, patients with cirrhosis, a high viral load and genotype 
1 tended to have a slower second phase viral decline (Table 3).Only for the subgroup 
of patients with a low viral load (cut-off < 2 x 106 copies/ml) the clearance of infected 
cells was significantly more rapid (p=0.002). 
Analysis of the individual viral dynamics showed similar results, with a median 
blocking efficacy of 99.88% and a half-life of infected cells of 67 hours (Table 4). 
Hand plotting of the viral load data suggested that the actual data did not completely 
follow a bi-phasic decline. To validate this observation we analysed the data without 
trying to make it fit into a bi-phasic model. A significant positive deviation from the 
calculated bi-phasic curve was observed between 32 till 120 hours after treatment 
initiation (Figure 3). In all 20 evaluable patients, a short rise in viral load followed the 
initial decline, creating a hump in the viral decline. This short rise in viral load was 
observed when sera were analysed by the NGI assay as well as by using the Cobas 
Amplicor assay (95% of the data comparable). 
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Table 2: Hev RNA negativity at week 4 of treatment. 
Variable PCR negativity at week 4 PCR negativity at week 4 
(Intention To Treat analysis) (Per Protocol analysis) 
ALL 70 MU IFN/week 71% (17/24) 77% (17/22) 
1 x 10 MU daily 67% (8/12) 73% (8/11) 
Schedule 
2x 5 MU daily 75% (9/12) 82% (9/11) 
Nonresponse 64% (9/14) 69% (9/13) 
Previous 
treatment Relapse Ino 
treatment 80% (8/10) 89% (8/9) 
45% (5/11)' 56% (5/9)' 
Genotype 
non-1 92% (12/13)' 92% (12113)' 
>2x106 50% (7/14) t 69% (7/12) t 
viral load 
< 2 x 106 100% (10/10) t 100% (10/10) t 
Yes 56% (6/11) 60% (6/10) 
Cirrhosis 
No 85% (11/13) 92% (11/12) 
"ITT analysis p=0.02, PP analysis p=0.12 
t ITT analysis p=0.02, PP analysis p=O.04 
97 
Chapter 7 
Tabel3: Estimated viral dynamics parameters by statistical analysis of all 
patients combined and by subgroup analysis. 
All 
Group 1 
Group 2 
Previous NR 
Others(RRlno 
Rx) 
Genotype 1 
Genotype non-1 
High viral load" 
Low viral load 
Cirrhosis (+) 
Cirrhosis (-) 
Initial load 
(Copies/ml) 
VO t 
6.17 
6.31 
6.06 
6.19 
6.12 
6.44 
5.95 
6.41 
5.82 
6.13 
6.19 
Virion 
clearance 
(1/day) 
c 
7.9 
7.4 
7.4 
7.1 
10.3 
7.9 
7.9 
7.8 
8.4 
9.5 
7.8 
Virus half-
life 
(hours) 
T1/2 
2.1 
2.2 
22 
2.4 
1.6 
2.1 
2.1 
2.1 
2.0 
1.7 
2.1 
Efficacy 
(percent) 
• 
99.89 
99.93 
99.81 
99.83 
99.96 
99.89 
99.88 
99.90 
99.89 
99.88 
99.92 
Infected cell 
death 
(1/day) 
/) 
0.22 
0.18 
0.24 
0.22 
0.21 
0.18 
0.24 
0.16 :I: 
0.31 :I: 
0.17 
0.25 
Infected cell 
half-life 
(hours) 
T,. 
77 
90 
70 
75 
79 
91 
70 
103:1: 
53:1: 
99 
68 
t: Initial viral load has been calculated with the assumption of an average 8 hours lag phase in viral 
decline 
:1:: p=0.0017 
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Tabel4: Calculated individual viral dynamics parameters using the model of 
Neumann et al. 
Initial load Virion Virus half~life Efficacy Infected cell I nfected cell 
clearance (hours) death half-life 
(Copies/ml) (1/day) (percent) (1/day) (hours) 
VOt c T," • S T," 
All (median) 7.19 7.38 2.25 99.88 0.23 67 
6.98 5.19 3.21 97.82 0.39 43 
2 6.66 5.92 2.81 99.64 0.35 47 
3 7.75 5.04 3.30 99.79 0.25 66 
4 6.77 4.31 3.86 99.02 0.06 264 
5 6.11 5.99 2.78 99.81 0.35 47 
6 7.25 6.36 2.62 99.09 0.44 38 
7 7.41 5.23 3.18 96.43 0.15 108 
8 7.19 8.01 2.08 99.93 0.14 121 
9 6.27 3.43 4.85 98.13 0.42 40 
10 6.67 4.01 4.15 98.44 0.18 92 
11 9.12 7.95 2.09 99.86 0.26 64 
12 7.25 6.90 2.41 99.69 0.17 97 
13 8.63 5.82 2.86 99.40 0.23 73 
14 7.54 2.05 8.10 88.13 0.35 48 
15 7.42 4.12 4.04 99.11 0.05 344 
16 No fit 
17 7.72 3.72 4.47 99.69 0.15 114 
19 6.42 13.86 1.20 97.31 0.02 673 
21 6.96 7.22 2.30 99.89 0.19 86 
22 6.28 6.14 2.71 99.94 0.18 90 
Patients No. 18 and 20 discontinued study medication due to non-compliance and side-effects. 
Patients No. 23 and 24 could not be included due to lack of sufficient samples. 
Patient No. 16 showed a rise in viral load; no correct individual fit could be obtained. 
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Figure 3 nonlinear curve fitting 
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In this figure, both group one and group 2 data is plotted without using a model that dictates a bi~ 
phasic decline. 
The linear rapid first phase and the linear slower second phase of viral decline are confirmed in this 
figure. However between these two phases a third phase can be obser..red that can not be explained in a 
bi-phasic model. Both for each patient separately (data not shown) as for the combined data shown in 
this figure a hump like curve can be plotted using the data between 32 hours and 120 hours after 
treatment initiation. 
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7.5 DISCUSSION 
With standard interferon-ribavirin therapy, about 50 percent of patients do not 
achieve a sustained response 2 Viral characteristics are the key factor in 
non response (high viral load and genotype 1) 2,9, and explanations are sought by 
suggesting resistant quasispecies strains or mutations in the NS5A region 10. In this 
study we treated a group of difficult to treat patients by a high initial interferon dose 
(10 MU). Our results show that high rates of viral suppression (>99% IFN efficacy) 
can be achieved in the large majority of patients, therefore the concept of interferon 
resistance is rather dose related than an intrinsic characteristic of the virus. 
This efficacy is comparable to that in a previously reported study in treatment narve 
patients who also received 10 MU interferon .. In that study, the efficacy was 
calculated for each individual separately. Our data are based on a group analysis 
that includes all data. When we analysed our data by using the individual method 8, 
the calculated median efficacy of blocking viral production was equally high (99.9%). 
No individual difficult to treat patient had an efficacy .of lower than 88% which 
challenges the concept of intrinsically resistant HCV to interferon and ribavirin. 
Our statistical method of group analysis is particularly suitable for group comparison 
and an additional tool for analyses of viral dynamics ", in particular for analyses of 
(sub)-groups. 
In this small randomised controlled trial the interferon efficacy was 99.9 versus 99.8% 
for the group with once daily treatment (group 1) versus twice daily (group 2). In 
addition, PCR negativity at week 4 did not show a Significant difference (67% versus 
75% for group 1 versus group 2 respectively). Therefore, the hypothesis that twice-
daily dosing would be more effective could not be supported. In view of the 
unexpected high efficacy found for interferon in this diff;cult to treat patient group and 
the high rate of PCR negativity at 4 weeks with once daily treatment, the lack of an 
additional effect of twice daily treatment comes less as a surprise. 
Biostatistical analysis showed that a high viral load (>2x1 06 copies/ml) was the only 
pre-treatment characteristic that had a significant correlation to a slower second 
phase viral decline (T'!2 of 103 versus 53 hours for high versus low viral load 
respectively, p=0.002). This negative correlation, previously reported by Neumann et 
aI., might reflect the pre-treatment immune reactivity of the host. Patients with a low 
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pre-treatment immune response against HCV tend to have a higher HCV RNA load, 
presumable due to a low spontaneous clearance rate of HCV infected hepatocytes. 
The observation that the immune status is reflected in both a high viral load and a 
slow second phase viral decline can explain the reported low sustained response 
rate in patients with a high viral load. The predictive value of early kinetics for 
sustained response has not been proven. However, results of this study make us 
believe that early viral kinetics yields more information for the prediction of sustained 
response than viral load alone. 
The main difference between the 2 methods of viral dynamics analysis was found in 
the estimaflon of the 'lnterferon efficacy. The mixed model analysis estimated a very 
narrow range for the interferon efficacy. An overall interferon efficacy of more than 
99% was estimated. If we compare this with the individual calculations, we find that 
for most cases, th',s very high efficacy can be confirmed, but in a few patients the 
interferon efficacy was found to be much lower (as low as 83%). The strength of the 
individual method is the accurate mathematical description of the viral decline where 
the strength of the mixed model analysis is in the comparison of groups. 
AnalysiS of the individual curves of viral decline revealed that a true bi-phasic decline 
does not fully describe the fall in viral load. An additional phase between the currently 
identified phases was observed in all evaluable patients. The pattern of this 
additional phase could be described as a hump in the viral load curve. In retrospect 
this additional phase could also be observed in data of others 12 Several possible 
mechanisms may be accountable for this observation. First, the efficacy of interferon 
may change after the first day due to down regulation of interferon receptors. If the 
immune-mediated second phase does not appear before 2-3 days after the first 
injection, a lag-period of diminished viral suppression is present. Second, the 
emergence of a viral species for which interferon has a lower efficacy might be 
another explanation for the hump in viral decline; since the hump was observed in all 
patients the second explanation is less likely. Research on viral quasispecies, 
interferon receptors and viral load decline in the I'lver are necessary to explain 
convincingly the hump in the viral load curve. 
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In conclusion, we have demonstrated a high interferon efficacy (>99%) can be 
reached in difficult to treat patients with a 4-week daily high dose of alpha-interferon, 
resulting in undetectable virus levels in 77% of the patients. There was no significant 
difference in viral dynamics parameters between patients receiving twice daily 5 MU 
interferon or once daily 10 MU interferon. A high clearance of infected cells was 
found in those patients with a low pre-treatment viral load, reflecting the key role of 
the host immune activity in the clearance of the virus. Lastly, a hump in the viral load 
curve was observed in all patients between the already known first and second 
phase, which calls for a further adjustment of the current viral dynamics models. 
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8.1 ABSTRACT 
Background Chronic hepatitis C patients with liver cirrhosis, high viral load, 
genotype 1 infection or those who have not responded to anti-viral treatment in the 
past have limited chances of clearing the virus. In this study we treated these "difficult 
to treat" patients with a new treatment schedule that combines high dose induction 
Interferon (IFN) and prolonged daily IFN-ribavirin treatment. 
Methods Twenty-four patients were included in this study with either genotype 1 
infection, cirrhosis, high viral load or previous non-response to anti-viral treatment. 
Patients were treated with 10 million units (MU) of Interferon (IFN) daily for 4 weeks 
followed by 5 MU/d until week 24, 3 MU/d until week 52 and 3 MU thrice weekly until 
week 76 in combination with 1-1,2 gram ribavirin daily. HCV RNA levels were 
assessed weekly until week 4 and at least once every 3 months thereafter, by a 
val'ldated assay with a detection limit of less than 500 copies/ml. 
Findings Both intention to treat (ITT) and per protocol (PP) analysis showed a high 
sustained virological response in this difficult to treat population (ITT 67%, PP 
80%).A virological response occurred rapidly (before 8 weeks of treatment) in all 
patients with a sustained response. Relapse after stopping therapy was observed in 
only 5%. Side-effects were observed frequently, 6 patients had to be hospitalised. 
(Patients with advanced cirrhosis had the lowest response rate (50%) and high side-
effect rate). 
Interpretation With this new treatment regiment that combines induction-, daily- and 
prolonged treatment it seems possible to cure chronic hepatitis C in the majority of 
patients that are considered difficult to treat, except those with advanced cirrhosis. 
Further clinical evaluation of this intensive interferon and ribavirin combination 
therapy is recommended in centres which can provide close patient monitoring and 
experienced hepatological support. 
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8.2 INTRODUCTION 
In the first decade after the licensure of interferon as therapy for chronic hepatitis C, 
results of treatment have shown stepwise improvement, firstly by prolongation of 
treatment from 6 to 12 months, secondly by combination of interferon with ribavirin 
1.2 Still, with the current recommended interferon-ribavirin combination therapy, a 
sustained clearance of the virus is observed in only 40-50% of patients 3·S 
For patients that have unfavourable patient or virus characteristics (cirrhosis, 
genotype 1 or 4, high viral load) the sustained response rate is much lower and 
ranges between 17-28% '.6. 
Failure to clear the virus can be observed at 3 different phases: during the initial (4-
12 weeks) treatment period (nonresponse, 40-50% of patients); during maintenance 
treatment after an initial response (breakthrough, about 10% of patients); after 
treatment discontinuation (relapse, 25-50% of patients). 
This study focuses on patients with a low chance of response to the current 
recommended schedule of combination therapy. We altered the treatment schedule 
in order to reduce the failure to respond at each of the three different phases. High-
dose daily induction therapy was given to optimise the initial response " followed by 
continued daily interferon and ribavirin combination in order to minimise break-
through; lastly: in order to prevent relapse, all patients were advised to prolong the 
standard treatment period of 12 months to a total duration of 18 months .. 
8.3 MATERIALS AND METHODS 
8.3.1 Study population 
Twenty-four patients with chronic hepatitis C, documented by hepatitis C antibody 
testing, the presence of plasma HCV RNA and histological findings consistent with 
fibrosis or cirrhosis, were included in. this study. Other clinical relevant concomitant 
diseases were excluded as previously described H 
All patients could be classified as "difficult to treat ", based on their baseline 
characteristics. Twenty-two patients (92%) were either non-responder to Interferon 
monotherapy or relapsers to combination therapy; 2 patients were treatment-naive 
cirrhotics. Of the total group 11 (46%) had Cirrhosis, of whom 7 could be classified as 
advanced cirrhosis (Siliriubin >17 ~mol/I or platelets <130x106/mm' ) 10. thirteen 
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(46%) had a genotype 1 or 4 11 infection and the mean viral load in the total group 
was more than 4x106 copies/ml. Nineteen patients (79%) had two or more 
unfavourable baseline characteristics. 
8.3.2 Treatment schedule 
All patients were admitted for the first 7 days of treatment and thereafter intensively 
monitored at the out-patient clinic. Patients received 10 Million Units of alpha-
interferon (Intron A) daily for 4 weeks followed by 5 Million Units daily until week 24,3 
Million Units daily until week 52 and 3 Million Units thrice weekly until week 76. 
Ribavirin was given twice daily orally in divided doses of 1,000 mg (weight <75 kg) or 
1,200 mg (weight >75 kg). 
Dose reduction was based on clinical intolerance or granulocytopenia below 0.5 x 
106/mm 3• In such cases interferon was reduced to the next level of the treatment 
schedule, ribavirin was reduced by steps of 200 mg/day. Combination therapy was 
discontinued in case of virological non-response, defined as detectable HCV RNA at 
week 12 and 16. 
8.3.3 Detection of HCV RNA 
Blood was drawn at baseline and at week 1, 2, 3, 4, 8, 12, 16, 24, 32, 48, 52, 76, 88, 
100 and 104. Blood samples were collected in plasma preparation tubes (Becton-
Dickenson) which were spun directly after collection in order to avoid RNA 
breakdown. A qualitative HCV RNA assay was used to asses viremia (modified in-
house Cobas Amplicor assay). The test was found to have a comparable sensitivity 
to the NGI assay (100 copies/ml and less than 500 copies/ml when validated by the 
Eurohep panel) 12 
8.3.4 Descriptive analysis 
The prevalence of HCV RNA negativity was calculated for the total population 
(Intention To Treat analysis) and for those who completed the treatment and follow-
up according to protocol (Per Protocol analysis). The initial response rate was 
calculated at the end of the induction phase (4 weeks). The breakthrough rate was 
calculated for those reaching HCV RNA negativity during treatment and the relapse 
rate at 6 months of follow-up for those who were HCV RNA negative at the end of 
treatment. 
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8.4 RESULTS 
The intention to treat population (ITT) consisted of 24 patients, 20 completed the 
study according to protocol (PP) (Fig 1). 
Figure 1: Trial profile 
24 consecutive patients started 
10 MU/IFN daily for 4 weeks 
1 I I I I 
22 patients completed 4 weeks 
, 
r------------------------~ 
2 patients stopped : 
(1cardial problems, 1 drug abuse) : 
------------------------~ 
of treatment 
~ I r I I I -1-P,;~~t~~pped-(fatig~;,-;e-;,k-6)-: I _________________________ J 
21* patients completed 
treatment (mean 72 weeks) 
1 I I I I 
20 patients completed 26 weeks 
r-------------------------
1 patient: no follow-up (developed : 
liver decompensation) : 
~------------------------~ 
follow-up 
The Intention To Treat population included all 24 patients who started treatment. The Per Protocol 
population comprised the 20 patients who completed treatment and follow~up according to the protocol 
Note: 2 patients stopped according to protocol (non-response at week 12-16) 
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A high initial response rate (ITT 67%, PP 75%) coupled to an additional response of 
about 10% during treatment and a very low break-through of 5%, led to an end of 
treatment response of 75% (ITT) - 85% (PP). Due to the very low relapse rate (5%) 
the sustained response in this group of difficult to treat patients was 67% (ITT) - 80% 
(PP) (Fig 2). 
Figure 2 HCV RNA response during treatment and follow-up of difficult to treat 
patients with chronic hepatitis C 
~ ~10 MUlday 
100 
5 MUlday I 3 MUlday I 3 MUI tiw I 
Ribavirin 1000M1200 mg/day FollowMup 
90 
80 ~ -pp 
• 70 
:E: 
~ 60 0 
~ 
« 50 % 
" > 40 
" X 
• ............ ~ 30 ~ 
0 
- -. .. _--_ ..... _. 
• ... -- . - - .. - - - ... • 20 ~ .- -. 
• ~ 
10 
0 I I I I I I 
048 24 52 76 104 
Weeks 
HCV RNA response during treatment and foliowRup of difficult to treat patients with chronic hepatitis C. 
Note the rapid disappearance of HCV RNA due to daily high dose interferon therapy, and the virtual 
absence of breakthrough after reduction at 1 month from 10 to 5 Mega Units. Breakthrough and 
relapse were only seen in 1 patient each of the per protocol cohort 
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Table I shows the results of treatment according to the baseline characteristics. 
According to the per protocol analysis all predefined sub-groups had a sustained 
response rate of 50% or more. For this intensive treatment schedule one patient 
characteristic, cirrhosis, and one virus characteristic, genotype, appear to be the key 
predictors of a sub-optimal response. When the effect of genotype and cirrhosis was 
analysed by univariate analysis (fisher-exact test), the presence of cirrhosis was a 
significant factor for not reaching a sustained viral response. 
Adverse events led to hospitalization in 6/24 patients (hepatic decompensation, de 
novo diabetes mellitus in association with jaundice and ascites, cardiac complaints, 
weight loss of more than 10%, infected injection site and decreased vision); 5 out of 
these 6 patients had cirrhosis. Combination treatment was discontinued in one of the 
above mentioned patients prior to week 52; it did occur in other patients due to drug 
abuse, cardiac complaints and fatigue with depression. 
The dose of Interferon was reduced in 8/24 and a reduction of ribavirin was observed 
in 5/24 patients; in the group of cirrhosis treatment was discontinued or reduced in 
7/11 versus 4/13 in the non-cirrhotic group. 
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Percentage HCV RNA negativity Percentage HCV RNA negativity 
(Intention To Treat analysis) (Per Protocol analysis) 
End of End of Follow- End of End of Follow: 
N= Week 4 N= Week 4 
Treatment up Treatment up 
ALL 24 16 (67%) 18 (75%) 16 (67%) 20 15 (75%) 17 (85%) 16 (80%) 
Genotype: 
Non-1 13 11 (85%) 11 (85%) 10 (77%) 11 10 (91%) 10(91%) 10 (91%) 
1 11 5 (45%) 7 (64%) 6 (55%) 9 5 (55%) 7 (78%) 6 (67%) 
Cirrhosis: 
Absent 13 11 (85%) 12 (92%) 12(92%) 12 11 (92%) 12 (100%) 12 (100%) 
Present 11 5 (45%) 6 (55%) 4 (36%) 8 4 (50%) 5 (68%) 4 (50%) 
Response to 
previous Rx: 
Nonresponder 14 9 (64%) 10(71%) 10(71%) 13 9 (69%) 10 (77%) 10 (77%) 
Relapser/na·'ve 10 7 (70%) 8 (80%) 6 (60%) 7 6 (86%) 7 (100%) 6 (86%) 
high sustained response with prolonged induction therapy 
8.5 DISCUSSION 
This exploratory study shows that in difficult to treat patients with chronic hepatitis C 
a high rate of sustained response can be obtained, albeit at the cost of a non-
neglectable incidence of clinical relevant adverse effects. 
The basis for the high sustained response rate was a high percentage of HCV RNA 
negativity by PCR at 4 weeks of treatment associated with daily high dose induction 
therapy, and the very low relapse rate «10%) due to prolonged treatment up to 1;1, 
years. High initial response rates have been described previously by Japanese 
investigators 7 and low relapse rates in other clinical studies with prolonged treatment 
13. This study is one of the first in which daily high dose induction for more than 4 
weeks was combined with prolonged maintenance treatment bridged by daily 
interferon therapy to prevent break-through. 
These favourable results contrast with the 17-28% sustained response in difficult to 
treat patients with the current recommended therapy and those with 2-4 weeks 
induction therapy followed by thrice weekly maintenance therapy in combination with 
ribavirin for 0.7-1 year 14.1'. 
When a daily high dose schedule is changed to a standard maintenance schedule of 
3 MU Interferon after 2-4 weeks, the percentage of HCVRNA negativity falls to about 
50% at the end of treatment 16. The duration of induction therapy needed to reach 
viral negativity using daily 5-10 MU combined with ribavirin is estimated to be 45-60 
days in previously untreated genotype 1 patients 17.This regimen was applied in our 
study. 
The duration of the maintenance therapy is likely another independent factor 
affecting the sustained response rate. Relapse rates for patients with undetectable 
HCVRNA are about 50% for 6 months therapy, 25% for 12 months and preliminary 
data indicates less than 15% for 18 months of combination therapy 8. 
The intensive treatment regiment in our study was expected to be associated with 
clinical significant non-compliance andlor adverse events. The incidence of non-
compliance and intolerability could kept low by intensive monitoring. Clinically 
relevant adverse events occurred mainly in patients with advanced cirrhosis. 
This early report, in a relatively small number of patients, suggests that the large 
majority of patients with chronic hepatitis C can be cured, except for those where 
cirrhosis has advanced to a stage with elevated bilirubin or low platelets. Having an 
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effective therapy for those patients with chronic hepatitis C most likely to develop 
liver-failure or a hepatocellular carcinoma is of major clinical significance for shifting 
the current trend of progressive morbidity and mortality due to hepatitis C. Further 
clinical evaluation of intensive interferon/ribavirin combination therapy is 
recommended in centres which can provide close monitoring and experienced 
hepatologic support. 
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9.1 ABSTRACT 
Although high dose interferon (IFN) induction treatment of hepatitis C viral (HCV) 
infection blocks viral production over 95%, dose reduction is often necessary due to 
clinical considerations. The effect of dose reduction on HCV kinetics was studied by 
allowing longitudinal changes in the parameters of viral dynamics. This model was 
used in a group of patients (N=15) with dose reduction from 10 to 3 MU of IFN daily 
in combination with ribavirin, in comparison to a control group (N=9) with no dose 
reduction. Dose reduction gave rise to a complex viral kinetic pattern, which could be 
only explained by a decrease in IFN effectiveness in blocking virion production. The 
benefit of the rapid initial decline following the high induction dose is lost after dose 
reduction. In addition, in some patients even the second phase viral decline slope, 
which is highly predictive of success of treatment, was impaired by the dose 
reduction resulting ',n smaller percentage of viral clearance in the dose reduction 
group. A rational strategy for a safe dose reduction is suggested based on individual 
patient viral kinetics. 
9.2 INTRODUCTION 
The hepatitis C virus (HCV) causes a slowly progressive liver disease, which may 
lead to cirrhosis, liver failure and liver cancer. Currently, about 10,000 patients die in 
the US from HCV related disease yearly and this number is expected to triple in the 
next 2-3 decades '. Anti-viral therapy is successful in arresting the progression of the 
disease in those patients who reach a sustained clearance of the virus, currently only 
40% of treated patients 2 Response to therapy with alpha Interferon injections thrice 
a week with or without additional ribavirin is thought to occur gradually over time, and 
research has focussed on improving efficacy by prolonging treatment up to 1 to 2 
years 2·4 However, reports on viral dynamics analysis show that response to 
interferon is very fast and that a 10 to 1000 fold decrease in viral load can be 
reached within 24 hours of treatment 5.7. The pattern of viral decline seems to be 
biphasic, with a rapid viral decline within the first 24-48 hours followed by a much 
slower second phase of viral decline. This biphasic decline is hypothetically caused 
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by a direct anti-viral effect of interferon in blocking virion production from infected 
cells '. 
A strong dependence of the viral decline in the first phase on the dose of interferon 
used has been described 5,8 Nevertheless, it has been shown that it is the second 
slope which is the best predictor for response to treatment 5,9,10, This slower second 
phase slope of viral decline has large variability between patients, and therefore 
cross sectional analysis of its dose dependence is hindered, Instead, here we 
investigated the longitudinal changes in viral dynamics in patients going through a 
dose reduction in order to asses the effect of dose on the second slope, The current 
model for HCV dynamics, in which the dynamical parameters are fixed during 
treatment, has been proven to correctly fit the observed biphasic viral decline in 
patients treated with fixed Interferon dosages'. However, in this study we adapted 
the model such that the dynamical parameters can change over time due to a 
change in dose, Lastly, we discuss the clinical implications of changes in the 
dynamics and suggest strategies for managing dose reduction, 
9,3 MATERIALS AND METHODS 
9,3.1 Study population 
All 24 HCV genotype-1 patients enrolled in our high-dose induction studies were 
evaluated, All patients met the inclusion and exclusion criteria previously described 
", Note that all patients in these studies were considered "difficult-to-treat", either 
because they were non-responders to previous treatment or had cirrhosis andlor high 
baseline viral load, Group 1 patients (N=9) received 10 MU of Interferon-a-2b (lFN, 
Intron-A, Schering-Plough) daily for 4 weeks. Group 2 patients (N=15) received 10 
MU of IFN daily for the first 3 days only, followed by 3 MU IFN daily from day 3 until 
day 28, In both groups, ribavirin was given orally in divided doses of 1,000-1,200 mg 
daily (according to weight >75 kg). Subsequently, all patients received a maintenance 
treatment of minimally 3 MU IFN daily for 52 weeks, The patients baseline 
characteristics (Table 1) were well balanced, except for a trend for larger number of 
cirrhotic patients in group 1, 
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Table 1 Patient baseline characteristics. 
Patient characteristics Group 1 Group 2 
Number of patients 9 15 
Median age 44 47 
MalelFemale 7/2 11 14 
Race (Caucasian 1 Asian) 7/2 15/0 
Pre-treatment RNA HCV 5.5. x 10 6 7.5 x 106 
Genotype 1 All All 
Median AL T at baseline 89 122 
Cirrhosis/No-cirrhosis 4/5 1 114 
* 6/3 Previous NR 1 other 11 14 
*) Non-sustained responder to previous therapy or previously untreated patients 
with cirrhosis and genotype 1. 
9.3.2 Detection of serum HCV RNA 
Plasma samples were collected frequently during the first 4 weeks of treatment for 
HCV RNA detection. Blood samples were collected in PPT tubes (Becton-Dickenson) 
which were spun directly after collection in order to avoid RNA breakdown. The spun 
PPT tubes 12 were then transported to the virology department where plasma was 
alliquoted in 5 separate tubes that were stored at -80°C. Plasma samples were 
obtained at day 0 (0, 4, 8, 12, 16 hours), day 1 (24,32 and 40), day 2 (48 and 56 
hours), day 3 (72 and 80 hours) day 4,5,67,10,14,17,21 and 28 after treatment 
initiation. 
Viral load was quantified using the COBAS AMPLICOR MONITORTM version 2 
(Roche). Since the linearity of quantitative assays for high numbers of viral copies 
has been questionable 13, we routinely diluted samples and re-tested, if the early 
quantification of that sample was higher than 106 copies/ml. 
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9.3.3 Mathematical Modelling 
Viral kinetics were analyzed using a modification of a previously described 
mathematical model for viral dynamics 5, for which the analytical solution is, 
V(t) = VO{A exp[-A1 (t - to)] + (1-A) exp[-A2(t - to)]} for (t > to) 
Where 
A1 ,2 =:h {(c + 0) ± [(c - 0)2 + 4(1 - 8)(1-'1) co]1/2} 
A = ("c-A2)/( A1 - A2) 
(Eq. 1) 
(Eq. 2) 
(Eq. 3) 
This formula contains several dynamical parameters (c, 0, '1 and ,,) which may vary 
per patient according to the best fit of the actual data, but are constant over time. c 
describes the clearance rate of free virus, with the corresponding virus half-life of 
In(2)/c. 0 describes the loss rate of productively infected cells, with the corresponding 
cellular half-life of In(2)/o. The effect of IFN can be modelled here either by a block of 
de-novo cell infection with '1 effectiveness (0~'1~1), or block of virion production with 
effectiveness ,,(0~8~1). The logarithmic drop in viral decline during the first phase 
(24-48 hours) of treatment can be approximated by log(1-,,). The 2'd phase slope can 
be approximated by £ times 0 when '1«1, or by 0 alone when '1=1. 
To investigate the effect of reducing treatment dose, aI/ the above dynamical 
parameters were allowed to change over time in the solution, e.g. for IFN 
effectiveness in blocking virion production, E, we use the function 8(t) : 
for t ~ t1 : 8 (t) = 8, (Eq.4) 
for t >t1: 8 (t) = ("'-"2 exp( -k(t-t1)) + "2 
where t1 is the time of dose change and k is a exponential rate representing how 
rapid does the change in IFN dose effect the change in the parameter. Thus, the 
blocking effectiveness starts at "1 (for t ~ t1), and changes with an exponential 
transition to"2 (after (t-t1)>>1/k). The same functional form was used to investigate 
also changes in '1 (from '11 to '12),0 (from 01 to (2), and c (from C1 to C2). 
It is important to note that we do not explicitly model in Eq. 1 the dynamics of viral 
replication after the dose reduction, but rather replace the fixed parameters by time 
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dependent parameters in the original analytical solution obtained with fixed 
parameters. Nevertheless, we have tested this approximation by simulating a 
modification of the original differential equation model 5 where changes in the 
dynamical parameters were allowed to change at the time of dose reduction. We 
found no significant difference between the simulation of the full modified differential 
equation model and the modified analytical solution. Since we only have 2-3 viral 
measurements immediately after dose reduction, we can not estimate the 
appropriate replication parameters and thus chose to use the simple approximation 
given in Eq 1. 
To estimate HCV viral kinetic parameters for each patient, the logarithm of V(t) in Eq. 
1 (using 8(t) from Eq. 4) was fit to the logarithm of the viral load data by a non-linear 
least squares method using the Madonna software (R.I. Macey and G.F. Oster, 
Berkeley, CA, USA). Two patients in group 2 were missing viral load data during the 
first week of treatment and one patient had a null response (less than 3 fold change 
in viral load during treatment) and therefore their viral kinetics could not be fitted. 
9.3.4 Statistical analysis 
The Fisher-exact test (2x2 tables) and the Chi-square test (NxN tables) were used to 
determine the statistical significance of the distribution of categorical variables 
between groups. The non-parametric independent (or related) Mann-Whitney rank 
sum test was used to determine the statistical significance of differences in 
continuous variables between the two groups (or of changes in the parameters within 
the same patients). Correlation among parameters, or between parameters and 
baseline values, was evaluated using the Spearman non-parametric test. 
Significance was established at P<O.05. 
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9.4 RESULTS 
The bi-phasic decline previously reported 5·7,14 describes the viral kinetics during the 
first month for all patients in group 1 (see Figure 1 and Figure 2a), for whom IFN 
dose was kept constant. In contrast, we observed a complex dynamic pattern for 11 
out of 12 evaluable patients in group 2 (see Figure 1 and Figure 2b-d), In these 
patients, a rapid decline occurred during the first day, followed by a slower decline on 
the second and third days, at which point a rapid increase in viral load (mean 0.8 
[range 0-1 ,3] log copies/ml) is observed within 24-48 hours after the reduction in IFN 
dose. Thereafter, viral load again declined with a mean exponential slope 
comparable to the second phase slope in group 1, 
We have tried to fit the viral kinetics of the patients in group 2 with several models, in 
each one of them allowing to change one parameter (8, 11, cor 0) at the time of dose 
reduction. The only model that was able to qualitatively reproduce the observed 
kinetics was the one which allowed a longitudinal change in the IFN effectiveness in 
blocking virion production (8) as function of the IFN dose (see Eq 4). By only allowing 
to change the IFN effectiveness in blocking de-novo infection (11), death rate of 
infected cells (0) or the clearance rate of free virions (c), it was not possible to fit the 
observed data. When assuming the major effect of IFN is to block virion production in 
a dose dependent way (1 >81>£2>0), it was possible to fit the data both with 11=0 or 
11=1, Thus it was not possible to determine if IFN also blocks de-novo infection, in 
addition to blocking virion production, or not. Varying 11 between 0 and 1 only gives 
rise to minimal changes in the estimate of £ and c, while somewhat affecting the 
estimate of 0 when 8 is smaller than 0.98 (minimal estimate of 0 obtained for 11=1, 
and maximal estimate for 11=0), Moreover, when allowing 8 to change at the time of 
dose reduction, it was not possible to rule out that the other parameters also change 
at the same time, 
For simplicity sake, and since our data only implies minute effects due to changes in 
the other parameters, we have assumed a change occurs only in e when estimating 
the dynamical parameters, In addition, we needed to estimate the transition rate k 
(see Eq, 4) from £1 to 82. It was not possible to get a unique estimate of k for each 
patient individually, with only 2-3 measurements during the rebound. Since using k=1 
up to 20 did not significantly affect the estimate of the other parameters, we have 
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assumed k=2 for all patients such that the effect of 81 vanishes within 24-48 hours 
after the dose reduction in accordance to the observed data. 
The estimates obtained by non-linear fitting of each patient's viral kinetics individually 
are given in Table 2. As expected the baseline viral load, the half-life of free virions 
and the initial effectiveness in blocking v',,'lon producflon, all related to the first phase 
decline, were similar between the 2 groups. Mean half-life of free virions for all 
patients was 3.0 hours ± standard deviation of 1.6 hours, similar to that derived in 
previous stud',es for IFN-a monotherapy (2.7 hours) 5. The mean effectiveness in 
blocking virion production for all patients was 95.6% ± 6.5% for the 10 MU IFN dose. 
For group 1 the non-linear fit (with Eq. 4) did not give rise to a Significant change in e 
over time, in accordance to the constant daily IFN dose used in these patients (see 
insert in Figure 2a). For group 2, however, a significant (p<0.005) decrease in 
effectiveness of blocking production was observed (see inserts in Figure 2b-d and 
Figure 3a) from an average of 81 =94% ± 8% to 82=69% ± 27%. The effectiveness of 
IFN with 10 MU (81) and with 3 MU (82) were pair wise correlated (R=0.8, P<0.001). 
Cross-sectionally there was no difference observed between the 2 groups in the 
death rate of infected cells (see Table 2) or in the second phase slope (see Figure 
3b). However, longitudinal analysis of group 2 patients revealed a significant 
decrease from the predicted second phase slope, which would have occurred without 
a dose reduction, to the actual slope after dose reduction in 4 out of 12 patients (see 
Figure 4a). These are the patients with the largest decrease (range 20% to 68%) 
from 8, to 82, since the second slope is a linear function of the IFN effectiveness in 
blocking production (8). 
The clinical consequences of the viral dynamics data relate to the predicted time of 
HCV RNA negativity, which is strongly dependent on the second phase slope. The 
predicted time to HCV-negativity with the bi-phasic model (median 3.5 weeks) was 
confirmed by the observed individual data of group 1 patients (median 4 weeks), and 
the dose-reduction model (with the reduced 3 MU dose) predicted the time to HCV-
negativity in group 2 patients (medians 12 and 14.5 weeks, see Table 3). Reducing 
the IFN dose to 3 MU daily decreased the predicted number of patients that would 
become HCV-negative within 12 weeks from 12/15 with the 10 MU dose to only 7115 
with the reduced 3 MU dose, as indeed confirmed by the actual individual data 
(8/15). 
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Group 1 (N=9) received a continues dose of 10 MU IFN daily for 28 days. Group 2 (dose reduction 
group, N=1S) reduced from 10 MU IFN daily to 3 MU IFN daily after 3 days of treatment. After the viral 
load data was log~transformed, the geometric means were calculated for the 2 groups for each time~ 
point of viral load measurement. The created mean viral for group 1 clearly shows a biphasic decline 
in viral load as previously described for chronic HCV. Viral decline in the patients with a IFN dose 
reduction (see line Group 2) is more complex: a rebound in viral load is observed coinciding with the 
time of IFN dose reduction. 
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Figure 2 A-O 
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In figure 2a the actual viral load measurements (see black dots) and the fitted viral decline curve using 
Eq. 1 (see black line) is presented of one of the paflents (No 1-1) who rece'lve 10 MU IFN da'ily for 28 
days. The actual decline in viral load in this patient is best described by the original bi-phasic model. 
In figure 2 bod the actual viral load (black dots) and the fitted viral decline using the modified model 
allowing for a change in IFN efficacy as described in Eq.5 is presented (see black line). The actual 
viral decline could only be correctly fitted by using our modified model. 
The striped black lines represent the calculated bi-phasic decline curve for a continues 10 MU lFN 
regimen in the patients of group 2 by fitting only the observed viral load during the treatment period of 
10 MU daily in the or'lginal model. 
The grey line represents the calculated viral decline curve as if a continues treatment of 3 MU IFN 
daily waS given from the start of treatment (only the viral load during 3 MU IFN are fitted). Note that 
the difference in the slope between the calculated decline curves for 10 MU versus 3 MU (black 
stripes versus grey lines) is dependent on the change in interferon efficacy after dose reduction (see 
inserts). Patients 2-H was calculated to become HeV RNA negative within 14 days if 10 MU IFN was 
continued (grey line figure 2-d), but after dose reduction the actual viral decline curved shifted 
dramatically due to a strong decline in JFN efficacy (see black striped line). 
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Table 2: Results of non-linear fitting of viral dynamics 
Initial viral/oad % blocking production Half-life \"J of free Half-life of infected cells (days) 
Patient (l) (log copieslml) virions (hours) 
During After reduction to 3 minimal and maximal estimates'''' 
10 MU qd MUqd 
1-A 6.9 98.4 --- 2.3 8.7 - 8.8 
1-8 6.9 99.9 --- 2.5 3.0 - 3.0 
1-C 6.7 99.5 --- 2.2 1.7 -1.7 
1-D 6.1 86.9 --- 1.9 7.8 - 9.0 
1-E 5.8 99.5 --- 5.3 4.4 - 4.5 
1-F 6.4 98.5 --- 6.4 3.2 - 3.2 
1-G 7.0 95.1 --- 1.8 6.1- 6.4 
1-H 7.1 99.8 --- 1.7 1.1-1.1 
1-1 7.4 98.9 --- 3.3 4.9 - 4.9 
Group 1'" mean (sId) 6.7 (0.5) 97.4 % (0.04) --- 3.0 hours (1.7) 4.5 - 4.7 days (2.6 - 2.8) 
2-A 7.3 93.0 62.5 1.8 4.8 - 7.7 
2-C 6.8 98.1 78.5 3.3 0.9-1.2 
2-E 6.7 93.8 86.0 3.3 7.1-8.2 
2-F 6.5 99.6 95.2 1.9 1.0-1.0 
2-G 7.2 97.8 85.0 3.3 4.0 - 4.7 
2-H 7.3 95.5 27.8 3.9 1.2-4.7 
2-1 6.1 98.1 88.0 1.1 11.8 -13.5 
2-J 7.1 99.9 98.0 1.6 3.4 - 3.4 
2-K 7.1 71.4 25.2 2.1 2.6 - 2.7 
2-L 6.3 99.6 99.6 6.9 2.2 - 2.3 
2-M 7.4 93.0 81.1 2.1 12.0 -14.8 
2-N 6.8 92.4 33.2 3.6 2.5 -7.7 
Group 2 (4) mean (sid) 6.9 (0.4) 94.3% (0.08) 69.1% n (26.6) 2.9 hours (1.6) 4.4 - 6.7 days (3.9 - 4.6) 
1) Fitting was not done for: patients 2-8 (non-detectable at day 2 on), 2-D (Null-response), 2-0 (missing data and rebound). 
2) For group 1 half-life of free virions is only a maximal estimate because only samples from 0, 8 and 24 hours were available. 
3) Minimal and maximal estimates of the half-life of infected cells was estimated assuming 11=1 and 11=0 respectively in Eq 2. 
4) No statistically significant differences in any parameter ber.'Ieen the two groups. 
H) Statistically significant (p<O.002) difference in percentage blocking production before and after dose reduction in group 2. 
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Interferon efficacy in blocking producflon (%) 'IS displayed for group 1 and group 2. For the patients 
that received a dose reduction after 3 days of treatment (group 2), both the efficacy for the initial, 10 
MU IFN daily period, is displayed as well as the reduced efficacy after the dose reduction to 3 MU 
daily. Note that the initial interferon efficacy bet-Neen group 1 and 2 does not differ. After the dose 
reduction the interferon efficacy is reduced'ln 11/12 patients in group 2 (see c.onnected black dots). 
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The slopes of the second phase decline (days-1) is represented per patient (black squares) for both 
groups. No differences between both groups could be observed in this study. 
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Figure 4 A and B 
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2 is related to the change in slope of the second phase viral decline (open circles: second phase slope 
before dose reduction; horizontal lines: second phase slope after dose reduction). 
In 4 patients the slope of the second phase reduces drastically, note that 3/4 of these patients have 
the largest reduction in interferon efficacy.The dashed line reflects the threshold of 0.13 days-1 below 
which no sustained response was observed. 
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The relation between the initial drop in viral load in log (x-axis) and the predicted change in the slope 
of the second phase (y-axis) due to dose reduction is displayed. In this figure the four different lines 
represent 4 possible responses in the viral load after dose reduction (ranging from a 0.25 up to 1 log 
increase in viral load as actually observed in this study).ln patients with a very steep initial drop in viral 
load (>2 log drop, corresponding with an IFN efficacy of more than 99%), the effect of dose reduction 
·IS minimal. Even is there would be a rebound in viral load of 1 log after dose reduction, the interferon 
efficacy would only be reduced from 99% to 90%, corresponding with a minimal change of the second 
phase slope. Patients with a more modest (1-2 log) initial drop, could experience a large change in the 
second phase slope if the increase of viral load is more than 0.5 log. In patients with <1 log initial 
decline, any change increase in viral load after dose reduction wilt lead to large changes in the second 
slope. 
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Table 3: Predicted and observed time to HCV RNA negativity 
Patient Predicted time (weeks) to Hev RNA Predicted tjTt't~WeekS) to HeV RNA First observedHCV RNA 
negativity(l)wiih 10 MU/daily negativit t with 3 MU/daily negativity" (weeks) 
1-A 11 --- 12( j 
1-B 2 --- 2 
1-C 1.5 --- 2 
1-D 12 --- 4-8 
1-E 2.5 --- 2 
1-F 3.5 --- 4 
1-G 10.5 --- 4-8 
1-H 1 --- 1 
1-/ 9 --- Positive at 24 weeks (3) (4) 
Group 1: HeV neg 9/ 9 patients --- 8/9 patients before 12 weeks 
2-A 9 16 Positive at 24 weeks (~J 
2-8 1 1 1 
2-C 1 2 1.5 
2-D Never Never Positive at 24 weeks (3) 
2-E 11 13 4-8 
2-F 1 1.5 1.5 
2-G 5.5 7 4-8 
2-H 3 10 12 -16 
2-/ 11 18 Positive at 24 weeks (3) 
2-J 3 5 4 
2-K 7.5 24 Positive at 24 weeks (3) 
2-L 1.5 1.5 1.5 
2-M 23 30 8-12 
2-N 4 16 Positive at 24 weeks (3) 
I 2-0 Never Never Positive at 24 weeks (3) 
Group 2: HeV neg 12/15 patients 7 115 patients 8/15 patients before 12 weeks 
--- ---- -
Detection fevel for HeV RNA negativity is at < 500 copies/ml. 2) Patient 1-0 had a viral breakthrough after 12 weeks and was Hev RNA positive at 24 weeks 
of treatment. 3) Patients with positive HCV RNA at 24 weeks stopped treatment according to protocol. 4) Patient 1-1 was non-compliant from 8 weeks on 
according to self-report. 
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9.5 DISCUSSION 
Our results indicate that the effect of IFN dose reduction on viral dynamics can be 
completely attributed to decrease in the effectiveness of IFN in blocking virion 
production (0). Changes in other parameters, such as blocking de-novo infection (1"\) 
loss rate of infected cells (8) and clearance rate of free virions (c), without a change 
in blocking production, can not reproduce the observed kinetics. The longitudinal 
dose dependence of the IFN anti-viral effectiveness observed here corroborates the 
dose dependence of IFN effectiveness previously described only cross-sectionally S 
The strength of the current results is that the dose dependence of the effectiveness 
cannot be attributed to baseline differences between the patients. Since longitudinal 
changes in the other parameters of this model (such as 1"\, 8 and c) do not give rise to 
Significant differences in the kinetics, we can not rule out combined effects of 
changes in the other parameters concomitantly with the change in effectiveness of 
blocking production (8). 
In turn, the dose dependency of the IFN effectiveness determines the result of both 
the 1" phase and the 2"' phase kinetics. The effectiveness in blocking virion 
production with 1 0 MU before dose reduction (mean 95.6% and a mean viral decline 
of 1.8 log cp/m I) was similar to that of a previous study with 10 MU IFN (96%) 5. 
However, we show that the benefit of the initial viral decline due to 3 days of high 
induction dose was lost after the dose reduction in almost all patients (see Figure 1). 
The effectiveness in blocking virion production with 3 MU after the dose reduction 
(mean 69.1 % and a mean viral decline of 0.7 log cp/m I) was similar to that estimated 
in a previous study with 3 MU IFN initially (70%) .. As a consequence, the viral 
kinetics after the dose reduction in group 2 patients is similar to the kinetics that 
would have been obtained if the patients had started with the reduced dose to begin 
with (see grey line in F',gure 2). 
In contrast to the 1" phase viral decline, which exponentially depends on the IFN 
effectiveness, the 2"' phase slope isa linear function of the effectiveness in blocking 
virion production. This slope is the most predictive parameter for treatment outcome, 
with a threshold of 0.13 days" below which no sustained response was observed 5.10. 
While the increase observed in viral load immediately after dose reduction can delay 
the time to negativity by several weeks at the most (see patients 2-J and 2-C in 
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Figure 2), the decrease in the second phase slope can radically reduce the chance 
for HCV-RNA negativity (see patient 2-H in Figure 2). Therefore the decrease in the 
second slope to below the 0.13 threshold in some patients (Figure 4a) could be 
crucial for their success of treatment. Indeed, the number of patients predicted to 
become HCV-negative within 12 weeks with the high induction dose was drastically 
reduced due to the dose reduction (compare the 10 MU column versus 3 MU column 
in Table 3). 
Interestingly, the results obtained here are for IFN and ribavirin combination 
treatment, while the results from previous studies 5.8.10 are for IFN monotherapy. On 
the other hand, in this study most patients are non-responders or cirrhotic rather than 
normal na'ive patients as in the previous studies 5,8. Thus, we can not conclude if 
ribavirin has an additive effect on initial viral decline or not. 
Is induction treatment beneficial at all considering that following dose reduction the 
virus rebounds back to the level it would reach anyway with the reduced dose? 
Previous studies with a somewhat longer period of induction treatment (14 days) do 
not show a consistent viral rebound as observed here 1'. Moreover, studies of 
prolonged induction treatment (up to 24 weeks with daily high dose of IFN) show a 
substantial decrease in relapse rate 16. Therefore, it could be suggested that an 
induction period of 3 days is too short, but longer induction periods, which continue 
until viral clearance, might give rise to continuous suppression of viral replication. 
However, since dose reduction is then applied when virus is undetectable it is not 
possible to monitor the changes in the viral decline slope. 
Alternatively, based on our observation that the second phase viral decline slope is 
related to the IFN effectiveness, we suggest a new treatment strategy for a safe dose 
reduction protocol. Patients with an initial (within 24-48 hours) viral load decline of 2 
log or more with 10 MU IFN treatment could reduce the dose to 3 MU already at 3 
days without a major loss of chance for successful treatment. This is due to the fact 
that even if the increase in viral load following dose reduction would be of 1 log, still 
the change in effectiveness and hence the change in the second slope would be only 
of 10% (Figure 4b). However, patients whose initial viral decline was only of 1-2 logs 
with 10 MU IFN induction treatment, could suffer from a significant decrease in their 
second phase slope if the viral load increases more than 0.5 log after the dose 
reduction. Therefore in these patients we would recommend to postpone the dose 
reduction until 2-4 weeks of treatment and monitor the viral load rebound carefully 
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during the dose reduction. Furthermore, patients with an initial viral decline of less 
than 1 log with 10 MU would most probably loose any chance for rapid second phase 
decline if the dose is reduced. In those patients we would recommend to continue the 
daily high dose as long as clinically possible. 
The results from this study allow to predict in which patients is dose reduction safe. In 
addition, the slope of the second phase viral decline can determine the actual 
probability for sustained response. Altogether, these results indicate that individual 
monitoring of viral kinetics could be used for rational modification of treatment 
resulting in a higher success rate and lower unnecessary therapy burden on the 
patients. 
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10.1 CHRONIC HEPATITIS C TREATMENT TODAY 
In the decade that hepatitis C virus infection (HCV) has been identified as a major 
cause of chronic liver disease, successive therapeutic regimens have resulted in 
clearance of virus in increasing proportion. The first effective treatment of chronic 
hepatitis C was alpha-Interferon, given as monotherapy 3 million units (MU) thrice a 
week (tiw) for 6 months 1,2 Such interferon monotherapy induces a sustained 
virological response only in a minority of patients (genotype 1: 2-9%, genotype non-1: 
16-21%) 3-5 Strategies to increase the antiviral activity included the adjustment of 
interferon dose, the frequency of administration, and the duration of therapy as well 
as combination of interferon with ribavirin. More recently a new form of alpha-
interferon (pegylated interferon) has been introduced. 
Prolongation of interferon therapy tiw till 12 months reduces the relapse rate and 
thereby increases the susta',ned response. rate (genotype 1: 9%, genotype non-1: 
36%) 4.5. The effects of increasing the dose of interferon from 3 MU upwards or 
increasing the frequency of administration from thrice weekly to daily have been less 
clear 6,7. 
Ribavirin, a guanosine analogue, lowers serum transaminases in many patients with 
chronic hepatitis C, but has no effect on serum HCV RNA levels 8,9. When used in 
combination with interferon, it increases the end of treatment response and reduces 
post treatment relapse 10.13. Recent large randomized placebo-controlled trials in the 
U.S. and abroad have confirmed the enhanced efficacy of combination interferon-
ribavirin therapy (sustained response in genotype 1: 17 to 29% for 6 vs 12 months 
therapy, genotype non-1: around 65% for both 6 and 12 months) 3,4 
Table 1: Sustained virological response percentage (6 months after end of treatment) 
IFN i IFN IFN-ribavirin i IFN-ribavirin 
! monotherapy monotherapy combination combination 
6 months 12 months 6 months 12 months 
Genotype 1 2% 9% 17% 29% 
Genotype non-1 * 16% 36% 
i 
66% 65% 
. Reflects data on genotype 2 and 3, data on genotype 4~6 are too limited for inclUSion In the table 
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Pegylated interferon is a slow release preparation of alpha-interferon, that maintains 
virus suppressive interferon levels for about a week; this formulation increases the 
end of treatment response and reduces breakthrough (sustained response in 
genotype 1: 27-28% for 6 vs 12 months monotherapy; genotype non-1 : 36-58% for 6 
vs 12 months monotherapy) 14.1'. Pegylated interferon in combination with ribavirin 
increases the sustained response rate significantly, but final outcome is similar to 
interferon plus ribavirin for 6 months therapy; it is improved for 12 months therapy 
(sustained response in genotype 1: 22-42% for 6 vs 12 months combination therapy; 
genotype non-1 : 62-82% for 6 vs 12 months combination therapy) 16 
Table 2: sustained virological response rates for pegylated interferon therapy 
PeglFN PeglFN Peg IFN- I PegIFN-
ribavirin ribavirin 
monotherapy monotherapy 
combination combination 6 months 12 months 6 months 12 months 
Genotype 1 27% 28% 22% 42% 
Genotype non-1 36% 58% 62% 82% 
i 
Although combination therapy and Peg-interferon represent marked improvements in 
our ability to treat chronic HCV infection, there are still approximately 50% of patients 
who will not respond to antiviral therapy. Currently, much attention is focused on 
patient or virus characteristics that can identify those patients that will or will not 
benefit from treatment. Large multi-center trials have identified variables that 
influence response to combination interferon-ribavirin therapy. The major pre-
treatment factors influencing the response rates in a clinically relevant way are the 
HCV genotype and the degree of fibrosis; with combination therapy, the viremia level, 
age and gender are of lesser significance 3.4,12. 
Since genotype 1 is the predominant genotype in the western world and the 
sustained response rate with combination therapy is only 28%-42%, more effective 
treatment for this large group is desirable. Another group of patients that currently is 
in need of better treatment is the patient with cirrhosis, in view of the fact that 
morbidity and mortality of chronic hepatitis C is predominantly in this category of 
patients 17. 
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Daily high doses of IFN have been used for years In Japan, resulting in high (more 
than 80%) initial response rates. In Rotterdam, treatment with daily high dose IFN 
was evaluated for the "difficult to treat" patients with genotype 1 or cirrhosis. Since 
the introduction of validated quantitative PCR assays for HCV RNA, monitoring the 
viral load during the initial treatment phase has become feasible 18.1'. Therefore, in 
order to evaluate the effect of the high daily dose regime the initial viral decline 
pattern was closely examined. Analysis of this viral decline during the first 4 weeks of 
treatment revealed a bi-phasic decline in nearly all patients 20-22. Twenty out of the 24 
included patients completed the study period 23. The first phase showed a mean drop 
in viral load of 2.3 log in 2 days (range 0.8-3.2). Fifteen patients declined rapidly 
during the first phase and were negative at 4 weeks. Three declined slowly and were 
expected to become HCV RNA seronegative before 26 weeks and 2 patients were 
unlikely to become seronegative within 26 weeks. In summary, treatment with daily 
h'lgh dose ',nterferon ',n Rotterdam was also found to result in 75% early virolog'lcal 
response. 
Daily high dose treatment has not been accepted in Western Europe and the USA 
since no lasting beneficial effect on sustained virological response has been shown. 
However, in Japan treatment duration has been limited to 6 months in all studies7; 
also in other studies the high relapse rate might be explained by insufficient 
treatment duration or by too rapidly lowering the dose 24 According to a large 
multicenter Benelux study 25, reductions in relapse rates to less than 10% can be 
obtained by prolonging combination therapy to 18 months. Therefore, the daily high 
dose interferon therapy (10 MU/d) in Rotterdam was combined with ribavirin, daily 
interferon was maintained for 12 months, the dose of interferon was lowered only 
after one month and again after 6 months and the total duration of therapy was 
prolonged to 18 months. As a result, this single centre study in "difficult to treat" 
patients showed marked improvements in inducing an end-of-treatment virological 
response up to 75%. (genotype 1: 67%, genotype non-1: 91 %; per protocol analysis) 
23. With an overall sustained response of about 70% with high dose prolonged 
therapy, it emerges that most patients with chronic hepatitis C, except those with 
advanced cirrhosis, can probably be cured of their illness. 
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10.2 TOMORROW: INTERFERON - RIBAVIRIN ADAPTED TO INDIVIDUAL 
VIRAL KINETICS 
Maximal results in viral clearance seem to be induced by a therapy that combines the 
high initial response rates, observed with high dose interferon (daily or pegylated), 
with the reduced relapse rates observed with prolonged (>12 months) therapy. 
However, due to side-effects and costs such a treatment regime is not feasible nor 
desirable for all patients. Since (pegylated) interferon and ribavirin therapy has a 
number of side effects that increase with dose and duration 4.5,6.16.26, and since not all 
patients need such an intensive treatment schedule, patients should be carefully 
selected. Currently, baseline characteristics are used to pre-select patients that 
receive 6 or 12 months treatment with interferon-ribavirin 27.28 A problem with this 
concept is that some patients with a slow decline in viral load might not reach a 
durable viral clearance within the pre-defined treatment period 28.29 Some patients 
with 6 months of therapy might have benefit from 12 months of treatment 28,29 and 
patients with genotype 1, high viral load and 12 months of therapy might have 
foregone a relapse by extending treatment to 18 months 24 Furthermore, about 60% 
of patients with genotype 1 or cirrhosis will not reach an sustained response. Early 
identification of these non responders could save considerably on side-effects and 
costs. Analysis of the viral decline of the first 4 weeks of treatment will likely identify 
all these patients (figure 1). 
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Figure 1 Response patterns in viral load decline 
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When looking at the individual decline patterns it appears that three different patterns of response are 
present: Nonresponse (NR), rapid viral response (RVR) and slow viral response (SVR) Nonresponse 
can further be divided in: patients with no drop in viral load at aJi (complete nonresponse). patients 
who have an initial decline in viral load but remain flat thereafter (flat) and patients who rebound after 
an initial decline (rebounders). 
We propose to start with standard or high dose therapy based on base-line 
characteristics. All patients with genotype 1 and a viral load of more than 2 million 
copies/ml or early, compensated cirrhosis could be advised to receive high dose 
(daily interferon 10MU or an equivalent pegylated interferon dose) combined with 
ribavirin. All other patients could start with standard dose combination therapy. 
Quantitative measurement at 5 time-points (start of treatment, day 2, week 1, week 2 
and week 4) would reveal the viral kinetics of each individual patient (figure 2). 
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Figure 2 Individual viral decline curve, constructed out of 5 quantitative HCV RNA 
measurements 
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According to the individual virus decline treatment could be altered within 6 weeks: 
a) Patients who show a rebound, flat or complete nonresponse pattern could 
either stop treatment (if they have been treated with a high daily dose) or change to a 
high daily dose (if they have been treated with the standard dose). 
b) All patients who show a slow viral response (projected serum HCV RNA 
negativity within 2-6 months) could be advised to continue treatment for 12-18 
months. 
c) Patients with a rapid viral response (serum HCV RNA negative within 1 month) 
could stop treatment after 6 months. 
With the average cost of $150 per quantitative HCVRNA test, an individual analysis 
of the viral decline pattern will cost about $600-750. Compared to the cost of 6 
months additional combination treatment ($6000 - 8000) 30, an early treatment 
discontinuation in patients with a rapid decline pattern could prove not only to lower 
side-effects but be cost effective as well. Instead of prescribing all patients a 
standard 48 weeks pegylated interferon and ribavirin therapy, that is simply not 
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effective enough for most genotype 1 patients and too intensive for most genotype 
non-1 patients, individual tailoring of antiviral therapy based on the initial viral decline 
will be a logic step forward in the treatment for chronic HCV patients. 
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11.1 INTRODUCTION 
Treatment for chronic hepatitis C emerged only a decade ago. Since the first 
treatment strategies the aim of the treatment shifted from lowering the AL T level, 
towards clearance of the Hepatitis C RNA in serum as the major endpoint of 
treatment. With the availability of standardised quantitative assays for the detection 
of HCV RNA in serum, the actual decline pattern of the virus itself could be monitored 
during treatment. With these data it became possible to conduct the v'"al kineflc and 
dynamic studies as presented in this thesis. These studies provided the basis for new 
treatment strategies for "difficult to treat" patients with chronic hepatitis C. 
11.2 ASSESSMENT OF VIRAL LOAD 
Qualitative HCV RNA analysis has been shown to be more informative than AL T 
levels for assessing the response to treatment, during treatment, at the end of 
treatment and after 6 months of follow-up. HCV RNA positivity after 4 weeks of 
therapy predicts uniformly nonresponse. However, a problem with qualitative assays 
is the constantly declining level of detection of HCV RNA; with new, more sensitive 
assays that are able to detect only a very small amount of circulating HCV RNA, 
early testing for HCV RNA will be more frequently positive than with older, less 
sensitive assays. This could lead to postponing the decision whether or not to stop 
treatment because of non-response. Quantitative HCV RNA assays can accurately 
assess the actual amount of v'"us at any given time during treatment and allow for 
early analysis of the drop in viral load. The actual drop in viral load will be suitable for 
the decision to stop or continue anti-viral treatment than one qualitaflve virus 
measurement. (chapter 2) 
In chapter 3 the validation of the newly available quantitative HCV RNA assays is 
described. Plasma samples frozen at -SOC of patients with chronic hepatitis C were 
sent to NGI laboratories in Los Angeles California, where they were tested with the 
Superquant™ assay. All samples were blinded, and test samples from a validated 
standard dilution series (EUROHEP dilution series for hepatitis C RNA, genotype 1 
and 3) were included. During the test phase of the samples, NGI laboratories was 
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visited by the investigator to observe the process. Besides testing all samples with 
the NGI assay, they were also analysed with a second quantitative assay (Roche 
Amplicor assay) in Rotterdam. Both assays performed equally well and the detection 
limit of the assays was calculated from the dilution series to be around 500 copies 
per milliliter plasma. This study was able to show that quantitative were both 
sensitive and specific and test results were linear over a wide range of viral load. 
11.3 DESCRIPTION OF THE DECLINE IN VIRAL LOAD 
(first aim of this thesis) 
With the Superquant™ assay for quantitative HCV RNA detection validated, all 
plasma samples of chronic HCV patients that were re-treated according to a protocol 
designed in 1991 were analysed. All patients in this study had previously received 
the standard treatment (3 mega-units Interferon thrice weekly for 6 months) without a 
response; re-treatment consisted of 10 mega units interferon daily for 5 days, 
thereafter 10 mega units was give thrice weekly until week 4. A gradual decline in 
viral load was expected to occur; however, nearly all decline in viral load occurred 
within 2 weeks of treatment. Close examination of the viral load decline within the 
first days showed a bi-phasic decline, with a rapid initial decline in all patients (alpha 
phase) and a much slower decline or even an increase thereafter (beta phase). Viral 
kinetics analysis revealed that the rapid decline in viral load corresponded with a half-
life of free virus of approximately 5 hours. Three out of 11 patients became sustained 
responders in this study: those 3 patients revealed a very fast clearance of the virus 
and no virus could be detected in plasma after 2 weeks of treatment. (chapter 4) 
In chapter 5, we responded to an article that stated that the viral load declined 
exponentially in chronic hepatitis C patients infected with genotype 1. However this 
study used only viral load data from the first days after treatment. In our study viral 
load data was available beyond 2 days of treatment. From this data we concluded 
that the viral load declines in at least 2 stages in genotype 1 patients. The rapid alpha 
phase and the slower beta phase were described for the first time in this article. 
Calculations on this second slower phase revealed that the viral decline was so slow 
in genotype 1 patients that virus-negativity could not be reached within 6 months. 
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Prolonged treatment was therefore advised for all chronic hepatitis C patients 
infected with genotype 1. 
11.4 INFLUENCE OF DOSE AND FREQUENCY OF INTERFERON ON VIRAL 
DECLINE 
(second aim of this thesis) 
In order to analyse the ',nfluence of changes to the standard treatment regimen, a 
study had to be conducted where a relative homogeneous group of HCV patients 
received a standard treatment, a higher and a more frequent interferon dose. The 
study displayed in chapter 6 included 4 groups of patients that had never been 
treated before, were all infected with genotype 1 and had no cirrhosis. The average 
viral decline was analysed for all groups. The group of patients that received the 
current standard dose of 3 mega units thrice weekly revealed the slowest decline, 
within the 4 weeks of treatment. 3 MU given daily improved the average speed of 
viral decline, but the fastest overall drop in viral load was observed when patients 
received 10 MU of interferon daily. This study indicated that daily dosage reveals a 
more gradual, faster decline in viral load, and that an increase of Interferon dose is 
followed by an increase in viral load decline. Theoretically, a faster decline in viral 
load could prevent the formation of mutations in the hepatitis C virus. A very rapid 
clearance of the virus leaves no time for mutations to emerge that are resistant to the 
given treatment. Since daily administration of interferon resulted in a more rapid 
decline of viral load, the next step was to evaluate the efficacy of twice daily 
administration of interferon. The rationale behind this schedule is the relative short 
half-life of Interferon of about 10 hours. However, viral kinetics analysis showed no 
benefit of a twice daily 5 mega units regimen when compared to daily 10 mega units 
of Interferon. (chapter 7) 
11.5 MATHEMATICAL MODELLING OF VIRAL DECLINE 
(third aim of this thesis) 
After it became apparent that a bi-phasic pattern in viral decline exists for hepatitis C, 
a way to mathematically model this pattern was examined. In the first studies 
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(chapter 4 and 5) a simple exponential curve was created for both phases of viral 
decline. Theoretically, from the alpha phase, the clearance of virus particles from the 
blood could be estimated, and from the beta phase the clearance of infected cells. 
In order to create a simple mathematical model that would describe the average 
decline in groups of patient (chapter 6) a linear regression analysis was performed on 
log transformed data. This model can be used by any physician and is a 
simplification of the actual decline pattern. 
Neumann et at. created a mathematical model that did incorporate the dynamical 
parameters that could explain the observed viral decline. Those parameters are: 
virus particle clearance (a), efficacy of Interferon in blocking the production of virus 
particles (e) and the death rate of infected cells. These parameters are all combined 
in one equation which provides information for individual patients. In chapter 7 this 
equation is used to obtain the individual viral dynamics parameters but additionally, 
a biostatistical mixed model with random effects was used that allowed us to analyse 
and compare groups rather than individuals. The benefit of individual modelling is 
that the exact decline pattern of the patient can be analysed. The benefit of the group 
analysis is the possibility to compare the viral decline between 2 groups of patients. 
11.6 CAN VIRAL KINETICS ANALYSES HELP US TO OPTIMISE THE 
TREATMENT FOR CHRONIC HEPATITIS C? 
(forth aim of this thesis) 
Ultimately, the goal of the viral kinetics research is to improve the current treatment 
results for chronic hepatitis C. Despite the introduction of ribavirin as addition to 
interferon and the prolongation of treatment to 1 year instead of 6 months, more than 
50% of the patients that are treated do not clear the virus. Moreover, those patients 
that need treatment the most (cirrhotics) have a sustained response rate below 20%; 
manay such patients have failed to clear the virus when previously treated. In chapter 
8 a study is displayed that focuses on improving treatment results in the "difficult to 
treat" patient group. Treatment has been optimised according to the results of 
previous viral kinetics research. First, the initial dose of interferon is increased to 10 
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MU daily for one month (optimise initial decline), second daily therapy was continued 
thereafter for 1 year (suppress break-through) and finally treatment was continued for 
1,5 year (prevent return of virus after stopping). In this pilot study this regirnen 
resulted in promising results: Initial response was improved, recurrence of virus 
during treatment was minimal and all but one patient that cleared the virus at the end 
of treatment remained negative for HCV. This led to an overall sustained clearance of 
the virus in nearly 70% of these "difficult to treat" patients. Downside of this treatment 
strategy was however the high incidence of side-effects that was observed in th"IS 
group. Twenty-fife percent of the patients had to be hospitalised. Adverse events 
occurred mainly in patients with advanced cirrhosis. 
After this, a study was conducted to analyse whether Interferon dosage could be 
lowered earlier without losing the improved viral clearance results. Rationale was that 
90 to 99.9% of the decline in viral load occurs within 2 days, therefore the new 
treatment schedule as described in chapter 9 lowered the dose of 10 MU interferon 
after 3 days to 3 MU Interferon daily. Unfortunately, the viral load rebounded directly 
after the treatment dose was lowered to 3 MU, resulting in a significant lower 
clearance rate of the virus within 4 weeks when compared to the patients that 
continued 10 MU of interferon daily. 
11.7 POSSIBLE BIOLOGICAL MECHANISMS OF INTERFERON 
(fifth aim of this thesis) 
Since the dose of interferon was lowered in each individual early after treatrnent 
initiation, the effect of this dose lowering on the level of viremia could be observed. In 
all other studies this analysis was hampered by the fact that the majority of patients 
reached undetectable levels of HCV RNA within 4 weeks, so dose reduction after 
that point did not allow for viral kinetic analyses. 
When the viral kinetic patterns were analysed it became apparent that the curves 
were not bi-phasic. Therefore the model described by Neumann had to be modified. 
The only modification that could correctly fit the observed data was the model that 
allowed for a continues change in the efficacy of interferon to block the production of 
the hepatitis C virus. Furthermore, individual analysis showed that in patients with a 
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very rapid decline (corresponding with a high interferon efficacy in those patients) 
within the first days, a dose reduction after 3 days did not really influence the viral 
decline curve. Contrary, in those patients with a slow initial decline the drop in viral 
load was reduced dramatically after the dose reduction. Individual monitoring of the 
viral load during treatment would allow for individual treatment schedules. Such a 
strategy would lead to early lowering of medication in those with a high interferon 
efficacy and continuing high dose treatment in those with a low interferon efficacy. 
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